<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables v1.3 20210610//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-3.dtd?><?SourceDTD.Version 1.3?><?ConverterInfo.XSLTName jats-oasis2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microbiol Spectr</journal-id><journal-id journal-id-type="iso-abbrev">Microbiol Spectr</journal-id><journal-id journal-id-type="publisher-id">spectrum</journal-id><journal-title-group><journal-title>Microbiology Spectrum</journal-title></journal-title-group><issn pub-type="epub">2165-0497</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">10913735</article-id><article-id pub-id-type="pmid">38298128</article-id>
<article-id pub-id-type="publisher-id">03689-23</article-id><article-id pub-id-type="doi">10.1128/spectrum.03689-23</article-id><article-id pub-id-type="publisher-id">spectrum.03689-23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="article-attributes"><compound-subject><compound-subject-part content-type="code">open-peer-review</compound-subject-part><compound-subject-part content-type="label">Open Peer Review</compound-subject-part></compound-subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">applied-and-industrial-microbiology</compound-subject-part><compound-subject-part content-type="label">Applied and Industrial Microbiology</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>New myxobacteria of the <italic toggle="yes">Myxococcaceae</italic> clade produce angiolams with antiparasitic activities</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1101-0939</contrib-id><name><surname>Walesch</surname><given-names>Sebastian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>Ronald</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author"><name><surname>Mahmoud</surname><given-names>Abdelhalim B.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author"><name><surname>Panter</surname><given-names>Fabian</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author"><name><surname>Bollenbach</surname><given-names>Sophie</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name><surname>M&#x000e4;ser</surname><given-names>Pascal</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author"><name><surname>Kaiser</surname><given-names>Marcel</given-names></name><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1042-5665</contrib-id><name><surname>Krug</surname><given-names>Daniel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1042-5665</contrib-id><name><surname>M&#x000fc;ller</surname><given-names>Rolf</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review and editing</role><email>Rolf.Mueller@helmholtz-hips.de</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Helmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarland University Campus</institution></institution-wrap>, <city>Saarbr&#x000fc;cken</city>, <country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Department of Pharmacy, Saarland University</institution></institution-wrap>, <city>Saarbr&#x000fc;cken</city>, <country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution>Helmholtz Centre for Infection Research (HZI)</institution></institution-wrap>, <city>Braunschweig</city>, <country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution>DZIF-German Center for Infection Research, partner site Hannover-Braunschweig</institution></institution-wrap>, <city>Braunschweig</city>, <country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution>Faculty of Pharmacy, University of Khartoum</institution></institution-wrap>, <city>Khartoum</city>, <country>Sudan</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution>Helmholtz International Lab for Anti-Infectives</institution></institution-wrap>, <city>Saarbr&#x000fc;cken</city>, <country>Germany</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution>Parasite Chemotherapy Unit, Swiss Tropical and Public Health Institute</institution></institution-wrap>, <city>Allschwil</city>, <country>Switzerland</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution>Faculty of Science, University of Basel</institution></institution-wrap>, <city>Basel</city>, <country>Switzerland</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name><surname>Tang</surname><given-names>Xiaoyu</given-names></name><aff><institution-wrap><institution>Shenzhen Bay Laboratory</institution></institution-wrap>, <city>Shenzhen</city>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Rolf M&#x000fc;ller, <email xlink:href="mailto:Rolf.Mueller@helmholtz-hips.de">Rolf.Mueller@helmholtz-hips.de</email></corresp><fn fn-type="COI-statement"><p>The authors declare no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>3</month><year>2024</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>01</day><month>2</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>2</month><year>2024</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>12</volume><issue>3</issue><elocation-id>e03689-23</elocation-id><history>
<date date-type="received"><day>16</day><month>10</month><year>2023</year></date>
<date date-type="accepted"><day>02</day><month>1</month><year>2024</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2024 Walesch et al.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Walesch et al.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-02-01"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="spectrum.03689-23.pdf"/><self-uri content-type="reviewer_comments" xlink:href="reviewer-comments.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>In the past century, microbial natural products have proven themselves to be substantial and fruitful sources of anti-infectives. In addition to the well-studied Actinobacteria, understudied bacterial taxa like the Gram-negative myxobacteria have increasingly gained attention in the ongoing search for novel and biologically active natural products. In the course of a regional sampling campaign to source novel myxobacteria, we recently uncovered new myxobacterial strains MCy12716 and MCy12733 belonging to the <italic toggle="yes">Myxococcaceae</italic> clade. Early bioactivity screens of the bacterial extracts revealed the presence of bioactive natural products that were identified as angiolam A and several novel derivatives. Sequencing of the corresponding producer strains allowed the identification of the angiolam biosynthetic gene cluster, which was verified by targeted gene inactivation. Based on bioinformatic analysis of the biosynthetic gene cluster, a concise biosynthesis model was devised to explain angiolam biosynthesis. Importantly, novel angiolam derivatives uncovered in this study named angiolams B, C, and D were found to display promising antiparasitic activities against the malaria pathogen <italic toggle="yes">Plasmodium falciparum</italic> in the 0.3&#x02013;0.8 &#x000b5;M range.</p><sec><title>IMPORTANCE</title><p>The COVID-19 pandemic and continuously emerging antimicrobial resistance (AMR) have recently raised awareness about limited treatment options against infectious diseases. However, the shortage of treatment options against protozoal parasitic infections, like malaria, is much more severe, especially for the treatment of so-called neglected tropical diseases. The detection of anti-parasitic bioactivities of angiolams produced by MCy12716 and MCy12733 displays the hidden potential of scarcely studied natural products to have promising biological activities in understudied indications. Furthermore, the improved biological activities of novel angiolam derivatives against <italic toggle="yes">Plasmodium falciparum</italic> and the evaluation of its biosynthesis display the opportunities of the angiolam scaffold on route to treat protozoal parasitic infections as well as possible ways to increase the production of derivatives with improved bioactivities.</p></sec></abstract><kwd-group><title>KEYWORDS</title><kwd>natural products</kwd><kwd>myxobacteria</kwd><kwd>drug discovery</kwd><kwd>anti-parasitic</kwd><kwd>structure elucidation</kwd><kwd>biosynthesis</kwd></kwd-group><counts><count count="2" count-type="supplementary-material"/><count count-type="authors" count="9"/><fig-count count="5"/><table-count count="1"/><ref-count count="47"/><page-count count="19"/><word-count count="10929"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>Many infectious diseases have lost their status as life-threatening conditions due to the discovery, development, and application of&#x02014;often natural products-based&#x02014;drugs. However, protozoal parasitic infections remain among the most devastating causes of mortality and morbidity, particularly in low- and middle-income countries. These diseases affect more than a billion people worldwide and are contributing to poverty and under-development (<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">&#x02013;</xref><xref rid="B3" ref-type="bibr">3</xref>). Examples from the WHO list of neglected tropical diseases (NTDs) are human African trypanosomiasis caused by <italic toggle="yes">Trypanosoma rhodesiense</italic> spp., Leishmaniasis caused by <italic toggle="yes">Leishmania</italic> spp., and Chagas disease (American trypanosomiasis) caused by <italic toggle="yes">Trypanosoma cruzi</italic>. (<xref rid="B4" ref-type="bibr">4</xref>) The three pathogens belong to the Trypanosomatidae, a large family of flagellated protozoa. Although malaria, caused by <italic toggle="yes">Plasmodium falciparum</italic>, is no longer considered an NTD since 2000, the disease still remains a major global health challenge due to its heavy death toll and high mortality levels among pregnant women and children in malaria-endemic African countries (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>The drugs currently available to treat these diseases are problematic given their serious adverse effects, limited efficacy, and most importantly the emergence of drug resistance. Therefore, there is an urgent need for the development of new, efficacious, safe, and cost-effective drugs for the fight against protozoal tropical diseases (<xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">&#x02013;</xref><xref rid="B8" ref-type="bibr">8</xref>).</p><p>Natural products remain a successful source of inspiration for the discovery of new drugs. About two-thirds of the drugs launched over the last 20 years derive directly or indirectly from natural resources (<xref rid="B9" ref-type="bibr">9</xref>). Moreover, of the 20 approved antiparasitic drugs, 9 were natural products or derivatives thereof (<xref rid="B9" ref-type="bibr">9</xref>). So far, all approved natural product-based drugs for the treatment of protozoal infections are plant-derived (<xref rid="B9" ref-type="bibr">9</xref>), but microbial natural products can also have promising bioactivities against protozoa, as displayed by fungal leucinostatins (<xref rid="B10" ref-type="bibr">10</xref>) or myxobacterial macyranone A (<xref rid="B11" ref-type="bibr">11</xref>) or chlorotonil A (<xref rid="B12" ref-type="bibr">12</xref>). As demonstrated by the structural diversity and variety of biological functions of the over 32,500 reported natural products, microorganisms are a prolific source of diverse and putatively biologically active metabolites (<xref rid="B13" ref-type="bibr">13</xref>). This plethora of natural products holds the promise of hidden bioactivities against often under-screened pathogens. Considering myxobacterial natural products, this is displayed by the recent findings of chondramides active against SARS-CoV-2 (<xref rid="B14" ref-type="bibr">14</xref>), the antitubercular properties of myxovalargin (<xref rid="B15" ref-type="bibr">15</xref>), or the potent anti-filarial activity of corallopyronin A through the inhibition of <italic toggle="yes">Wolbachia</italic> endosymbionts (<xref rid="B16" ref-type="bibr">16</xref>). Moreover, evaluation of the biosynthesis can be used to improve production titers in the heterologous expression of a natural product, as displayed for corallopyronin A (<xref rid="B17" ref-type="bibr">17</xref>), or to heterologously produce improved derivatives of a natural product family, as displayed for disorazoles (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>Following the initial purification of the antifungal ambruticin from a <italic toggle="yes">Sorangium</italic> sp. strain (<xref rid="B19" ref-type="bibr">19</xref>), myxobacteria as a group have increasingly gained attention as prolific producers of natural products. Their immense potential to produce compounds with novel chemical scaffolds and a wide range of biological activities is displayed by their large genomes with many biosynthetic gene clusters (BGCs), as well as the over 600 known myxobacterial natural products (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Taking into account that the majority of myxobacterial taxa has not been isolated yet (<xref rid="B22" ref-type="bibr">22</xref>) and that increasing phylogenetic diversity in myxobacteria entails increasing chances to find new chemical scaffolds (<xref rid="B23" ref-type="bibr">23</xref>), sampling campaigns to find, isolate and cultivate novel myxobacteria are a promising undertaking.</p><p>In this study, we describe the isolation of new myxobacterial producers of natural products leading to the discovery of four novel derivatives of the known natural product angiolam A (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Whole-genome sequencing of the new strains allowed the identification of the angiolam biosynthetic gene cluster that was verified by gene disruption in the genetically amenable producer <italic toggle="yes">Pyxidicoccus fallax</italic> An d48 (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Furthermore, we report the sub-micromolar bioactivities of several novel angiolam derivatives against the malaria pathogen <italic toggle="yes">Plasmodium falciparum</italic> that might make it an option for the development of future anti-malarial drugs.</p></sec><sec sec-type="results|discussion" id="s2"><title>RESULTS AND DISCUSSION</title><sec id="s2-1"><title>New producers of angiolam</title><p>As part of our ongoing efforts to isolate, investigate, and cultivate new myxobacterial strains as producers of novel and bioactive natural products, we launched a regional citizen science campaign named &#x0201c;MICROBELIX&#x0201d; (<ext-link xlink:href="http://www.microbelix.de" ext-link-type="uri">http://www.microbelix.de</ext-link>). In this project, soil samples were taken by members of the general public and channelled into the institute&#x02019;s strain isolation and characterization workflow. Among the isolates from this sampling campaign, strain MCy12716 caught our attention because its crude extract displayed anti-parasitic activities in an initial screening. Ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) analysis of the bacterial extract followed by dereplication of the secondary metabolite profile of MCy12716 revealed decent production of the myxobacterial antibiotic angiolam A (1), previously described from <italic toggle="yes">Pyxidicoccus fallax</italic> An d30 (formerly classified as <italic toggle="yes">Angiococcus disciformis</italic> strain An d30, <xref rid="F1" ref-type="fig">Fig. 1</xref>) (<xref rid="B25" ref-type="bibr">25</xref>). In addition, a number of compounds with similar fragmentation patterns suggestive of similar chemical scaffolds were observed (<xref rid="F2" ref-type="fig">Fig. 2A and B</xref>). However, MCy12716 showed strong variations in angiolam production within subsequent cultivations; hence, we searched for an alternative strain showing more stable production patterns. Thus, strain MCy12733 was eventually chosen for further analysis of the extended angiolam compound family. Based on phylogenetic analysis, strains MCy12716 and MCy12733 represent two novel producers of angiolams, which are located in a phylogenetically divergent clade compared to the original producer strains An d30 and An d48 (<xref rid="F1" ref-type="fig">Fig. 1</xref>). The two novel isolates clustered within the <italic toggle="yes">Pyxidicoccus trucidator-Pyxidicoccus caerfyrddinensis-Pyxidicoccus xibeiensis</italic> clade, while the previously known angiolam producers branched with <italic toggle="yes">Pyxidicoccus fallax</italic>. The biosynthetic ability to produce angiolam, therefore, seems to be strongly correlated to the genus <italic toggle="yes">Pyxidicoccus</italic>.</p><fig position="float" fig-type="figure" id="F1"><label>Fig 1</label><caption><p>Phylogenetic tree (MrBayes) inferred from 16S rRNA gene sequence showing the position of angiolam-producing strains (bold) in the <italic toggle="yes">Myxococcus</italic>-<italic toggle="yes">Pyxidicoccus</italic> clade. The values at nodes represent the posterior probability. The tree is rooted with <italic toggle="yes">Citreicoccus inhibens</italic>. Bar, 0.01 nucleotide substitution per site.</p></caption><graphic xlink:href="spectrum.03689-23.f001" position="float"/></fig><fig position="float" fig-type="figure" id="F2"><label>Fig 2</label><caption><p>The angiolam compound family and their production. (<bold>A</bold>) Extracted ion chromatograms of angiolam A (1, middle, dark blue/white) and its derivatives in MCy12733. Right box: angiolams B (2, light blue), C (3, light green), and D (4a/4b, blue). Left box: angiolams E (light blue) and G (dark green). (<bold>B</bold>) Feature-based molecular network, constructed by GNPS, of the angiolam compound family. Derivatives that were observed in Cy/H medium and subsequently purified are marked black. Angiolam F (5, blue) was observed and purified from Cy/H with additional 2.5 g/L <sc>l</sc>-valine. Angiolam derivatives that could not be purified due to low production yields are marked gray. The <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> ratios of the main ion in HPLC-MS measurements are indicated with the respective angiolam derivatives. Main ions, retention times, and sum formulae for the observed angiolam derivatives can be found in Table S9. (<bold>C</bold>) Relative production of angiolams A (1), B (2), and D (4a/4b) of MCy12733, when cultivated in different media. Data for all angiolam derivatives can be found in Tables S10 and S11.</p></caption><graphic xlink:href="spectrum.03689-23.f002" position="float"/></fig></sec><sec id="s2-2"><title>Identification, production, and structure elucidation of novel angiolam derivatives</title><p>In order to obtain a better overview of the natural product repertoire of MCy12733, the strain was cultivated in a standard Cy/H medium, and the resulting extracts were subjected to an untargeted metabolome mining workflow, using feature detection with subsequent MS/MS-based molecular networking according to the GNPS method (<xref rid="B28" ref-type="bibr">28</xref><xref rid="B29" ref-type="bibr">&#x02013;</xref><xref rid="B30" ref-type="bibr">30</xref>). Evaluation of these data showed that the MS/MS spectra of known angiolam A (1) cluster with MS/MS fragmentation spectra of five additional, to date unknown angiolam congeners (<xref rid="F2" ref-type="fig">Fig. 2B</xref>).</p><p>As several of these observed angiolam-like compounds were produced in very low levels, a cultivation media screening was performed to improve their production. Cultivation of MCy12733 in RG5 medium improved the production of most observed angiolam derivatives two- to threefold (<xref rid="F2" ref-type="fig">Fig. 2C</xref>; Tables S10 and S11). Analysis of the new extracts by MS/MS feature-based molecular networking showed the production of seven additional previously unknown angiolam derivatives, although mostly in trace amounts only (Fig. S1).</p><p>As production levels of the minor angiolams were small, the effect of added amino acids and polyketide precursors on the production of angiolam derivatives was tested. The addition of 2.5 g/L <sc>l</sc>-valine to Cy/H medium improved the production of novel angiolam D (4a/4b) about sixfold (<xref rid="F2" ref-type="fig">Fig. 2C</xref>; Tables S10 and S11). Production of all other angiolam derivatives was reduced about fourfold under these conditions making this a good example of precursor-guided steering of the angiolam biosynthesis. Further analysis of the extract with MS/MS feature-based molecular networking also led to the observation of novel angiolam F (5) that was only produced in cultivations with <sc>l</sc>-valine added to the production medium (<xref rid="F2" ref-type="fig">Fig. 2B</xref>).</p><p>In order to allow compound isolation, angiolams were produced in large-scale cultivations of MCy12733 using different media and subsequently purified by preparative HPLC and, in the case of angiolam derivatives C (3) and D (4a/4b), further separated by supercritical fluid chromatography.</p><p>As part of compound purification efforts, angiolam A was also isolated and its known structure was verified. High-resolution electrospray-ionization mass spectrometry (HRESI-MS) of angiolam A (1) shows a [M-H<sub>2</sub>O + H]<sup>+</sup> signal at <italic toggle="yes">m/z</italic> 570.3785 (calc. 570.37889 &#x00394; = 0.68 ppm) that corresponds to a molecular sum formula of C<sub>34</sub>H<sub>53</sub>NO<sub>7</sub> for [M]. The sum formula and the resulting nine double bond equivalents (DBEs) match the reported structure of angiolam A (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Comparison of <sup>1</sup>H, <sup>13</sup>C, and HSQC NMR spectra of 1 with authentic angiolam A confirmed the purified compound as angiolam A. Following the biosynthetic logic of angiolam A, we propose and employ a numeration for this family of natural products (<xref rid="F3" ref-type="fig">Fig. 3</xref>).</p><fig position="float" fig-type="figure" id="F3"><label>Fig 3</label><caption><p>Structures of known angiolam A and novel derivatives A, B, C, D<sub>1</sub>, D<sub>2</sub>, and F. Differences between angiolam A and novel derivatives are highlighted in the respective structures.</p></caption><graphic xlink:href="spectrum.03689-23.f003" position="float"/></fig><p>Angiolam B (2) shows a HRESI-MS [M + H]<sup>+</sup> signal at <italic toggle="yes">m/z</italic> 586.3748 (calc. 586.37385 &#x00394; = 1.62 ppm), corresponding to the molecular sum formula of C<sub>34</sub>H<sub>51</sub>NO<sub>7</sub> that has an unsaturation degree of 10 DBEs. With respect to the respective spectra of angiolam A, the <sup>13</sup>C NMR spectrum of 2 displays a further carbonyl signal at <italic toggle="yes">&#x003b4;</italic><sub>C-5</sub> 210.2, and the HSQC NMR spectrum lacks the signal corresponding to the hydroxylated methine 5 in the side chain of 1. HMBC NMR correlations of the surrounding H-3, H-6a, H-6b, H-7a, H-7b, and H-28 to this carbonyl signal demonstrate its location as C-5.</p><p>The HRESI-MS signal of the angiolam C (3) ion [M-H<sub>2</sub>O + H]<sup>+</sup> at <italic toggle="yes">m/z</italic> 572.3955 (calc. 572.39455 &#x00394; = 1.66 ppm) points to the molecular sum formula C<sub>34</sub>H<sub>55</sub>NO<sub>7</sub> for [M] with eight DBEs. Similar to angiolam B, angiolam C differs from angiolam A in the side chain. The HSQC NMR spectrum of 3 lacks the signals belonging to the terminal alkene of 1 but displays a new methyl group (<italic toggle="yes">&#x003b4;</italic><sub>C-1</sub> 14.1 and <italic toggle="yes">&#x003b4;</italic><sub>H-1</sub> 0.97) and a new methylene group (<italic toggle="yes">&#x003b4;</italic><sub>C-2</sub> 20.8 and <italic toggle="yes">&#x003b4;</italic><sub>H-2</sub> 2.03). COSY NMR correlations between this methylene group with the methyl group, as well as with H-3, show that angiolam C is fully saturated at the end of the side chain.</p><p>Evidence from the HRESI-MS [M-H<sub>2</sub>O + H]<sup>+</sup> signal at <italic toggle="yes">m/z</italic> 584.3953 (calc. 584.39455 &#x00394; = 1.28 ppm) suggested that angiolam D (4a/4b) possesses a molecular sum formula of C<sub>35</sub>H<sub>55</sub>NO<sub>7</sub> for [M] and nine DBEs. In contrast to the angiolam derivatives described above, angiolam D seems to be a mixture of one main and several minor components with very similar retention times (Fig. S2). Consequently, the purification workflow yielded the mixture of angiolam D<sub>1</sub> (4a) as major and angiolam D<sub>2</sub> (4b) as minor component. However, it was possible to elucidate the structures of 4a and 4b out of the same data set of 1D and 2D NMR spectra.</p><p>The difference between angiolams A and D is located within the macrocycle. While 1 holds methyl residues at C-24 and C-26, they are exchanged by an ethyl residue at C-26 in 4a and at C-24 in 4b. In 4a, this is demonstrated by the HSQC NMR signals of a methyl group (<italic toggle="yes">&#x003b4;</italic><sub>C-34&#x02019;</sub> 14.0 and <italic toggle="yes">&#x003b4;</italic><sub>H-34&#x02019;</sub> 1.01) and a diastereotopic methylene (<italic toggle="yes">&#x003b4;</italic><sub>C-34</sub> 20.6, <italic toggle="yes">&#x003b4;</italic><sub>H-34a</sub> 2.35, and <italic toggle="yes">&#x003b4;</italic><sub>H-34b</sub> 2.29). The methyl protons H-34&#x02032; show COSY-NMR correlations to the methylene protons H-34a and H-34b and HMBC-NMR correlations to the olefinic C-26 (<italic toggle="yes">&#x003b4;</italic><sub>C-26</sub> 135.1). Furthermore, the HMBC correlations of the methylene protons H-34a and H-34b to C-25 (<italic toggle="yes">&#x003b4;</italic><sub>C-25</sub> 141.3), C-26 (<italic toggle="yes">&#x003b4;</italic><sub>C-26</sub> 135.1), and C-27 (<italic toggle="yes">&#x003b4;</italic><sub>C-27</sub> 167.4), as well as the HMBC correlation between H-25 (<italic toggle="yes">&#x003b4;</italic><sub>H-25</sub> 6.39) and C-34, demonstrate the structure of angiolam D<sub>1</sub>. The ethyl residue in 4b is indicated by the HSQC NMR signals of a diastereotopic methylene (<italic toggle="yes">&#x003b4;</italic><sub>C-33</sub> 24.2, <italic toggle="yes">&#x003b4;</italic><sub>H-33a</sub> 2.00, and <italic toggle="yes">&#x003b4;</italic><sub>H-33b</sub> 1.33) and a methyl group (<italic toggle="yes">&#x003b4;</italic><sub>C-33</sub> 11.2 and <italic toggle="yes">&#x003b4;</italic><sub>H-33</sub> 0.86). COSY NMR correlations of methylene protons H-33a and H-33b to H-24 (<italic toggle="yes">&#x003b4;</italic><sub>H-24</sub> 2.46), as well as to the methyl-group H-33&#x02032; (<italic toggle="yes">&#x003b4;</italic><sub>H-33&#x02019;</sub> 0.86), show that these signals belong to an ethyl residue that is bound to C-24. This is further evidenced by HMBC-NMR correlations of H-23 (<italic toggle="yes">&#x003b4;</italic><sub>H-23</sub> 3.84) and H-25 (<italic toggle="yes">&#x003b4;</italic><sub>H-25</sub> 6.41) to C-33 (<italic toggle="yes">&#x003b4;</italic><sub>C-33</sub> 24.2) and reciprocal HMBC correlations between the methine H-24 (<italic toggle="yes">&#x003b4;</italic><sub>C-24</sub> 43.2 and <italic toggle="yes">&#x003b4;</italic><sub>H-24</sub> 2.46) and the methyl-group H-33&#x02032; (<italic toggle="yes">&#x003b4;</italic><sub>C-33</sub> 11.2 and <italic toggle="yes">&#x003b4;</italic><sub>H-33</sub> 0.86).</p><p>Angiolam F (5) shows a HRESI-MS [M-H<sub>2</sub>O + H]<sup>+</sup> signal at <italic toggle="yes">m/z</italic> 598.4121 (calc. 598.41025 &#x00394; = 3.09 ppm), corresponding to the molecular sum formula of C<sub>36</sub>H<sub>57</sub>NO<sub>7</sub> for [M] and nine DBEs. Similar to angiolam D, a mixture of one major and several minor components can be seen in the crude extracts (Fig. S2). However, the purification workflow resulted in one pure natural product. Compared to 1, the HSQC NMR spectrum of 5 lacks the methyl groups 33 and 34. Instead, it displays two slightly different methyl groups at <italic toggle="yes">&#x003b4;</italic><sub>C-33</sub> 11.2, <italic toggle="yes">&#x003b4;</italic><sub>H-33</sub> 0.86 and <italic toggle="yes">&#x003b4;</italic><sub>C-34</sub> 13.6, <italic toggle="yes">&#x003b4;</italic><sub>H-34</sub> 0.99 as well as two methylene groups at <italic toggle="yes">&#x003b4;</italic><sub>C-33</sub> 24.2, <italic toggle="yes">&#x003b4;</italic><sub>H-33</sub> 1.98 and <italic toggle="yes">&#x003b4;</italic><sub>C-34</sub> 20.7, <italic toggle="yes">&#x003b4;</italic><sub>H-34</sub> 2.34, similar to the signals belonging to the ethyl residues in 4a and 4b. As described above, COSY NMR correlations of methylene H-33 (<italic toggle="yes">&#x003b4;</italic><sub>H-33</sub> 1.98) to H-24 (<italic toggle="yes">&#x003b4;</italic><sub>H-24</sub> 2.45) and the methyl group H-33&#x02032; (<italic toggle="yes">&#x003b4;</italic><sub>H-33&#x02019;</sub> 0.86) identify an ethyl residue bound to C-24. Furthermore, methyl group H-34&#x02032; (<italic toggle="yes">&#x003b4;</italic><sub>H-34</sub> 0.99) shows COSY correlations to methylene H-34 (<italic toggle="yes">&#x003b4;</italic><sub>H-34</sub> 2.34) and HMBC-NMR correlations to olefinic C-26 (<italic toggle="yes">&#x003b4;</italic><sub>C-26</sub> 136.6), pointing toward an ethyl residue, bound to C-26. The identity and location of both ethyl residues within the macrocycle are further evidenced by HMBC-NMR correlations, as elaborated for 4a and 4b.</p><p>Due to their low production yields, angiolam derivatives E and G could not be purified in amounts sufficient for NMR-based structure elucidation.</p><p>Considering a common biosynthetic route for angiolam A and its derivatives, it was deemed likely that they are produced by a set of enzymatic domains involved in polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) hybrid-type biosynthesis. In the biosynthetic assembly line, small parts of the PKS-NRPS megaenzymes, so-called domains control the incorporation of single building blocks into the growing scaffold and determine the stereochemistry of the emerging natural product. Therefore, we propose that the reported stereochemistry of angiolam A should also be found in all newly described derivatives (<xref rid="F3" ref-type="fig">Fig. 3</xref>).</p></sec><sec id="s2-3"><title><italic toggle="yes">In silico</italic> analysis of the angiolam BGC and biosynthesis hypothesis</title><p>The discovery and understanding of the biosynthetic pathway for a given natural product class provide valuable insights that can be used to improve the production of these natural products or alter its biosynthesis towards the production of novel derivatives.</p><p>In order to find the biosynthetic origin of the angiolam compound family, genome sequences of both novel producers MCy12716 and MCy12733 were obtained by Illumina sequencing. Analysis of both sequences with antiSMASH (<xref rid="B32" ref-type="bibr">32</xref>) together with retro-biosynthetic considerations pinpointed a candidate polyketide synthase-nonribosomal peptide synthetase (PKS-NRPS) hybrid cluster with 12 modules spanning five genes. Alignment of the core BGC and its flanking regions was used to determine the likely cluster borders of the angiolam BGC. According to the similarities of both sequences, the <italic toggle="yes">ang</italic> BGC comprises a total of 14 genes spanning a 78.5 kb region. Detailed analysis of the genes in the <italic toggle="yes">ang</italic> BGC in MCy12733 was carried out by BLAST searches against the NCBI database (see below and Tables S20 and S21; Fig. S3). Interestingly, the genome of <italic toggle="yes">P. caerfyrddinensis</italic> CA032A, the closest described relative of MCy12733, harbors genes coding for proteins highly similar to the ones of the putative ang BGC. While these genes are present in the same order in both strains, <italic toggle="yes">P. caerfyrddinensis</italic> lacks the PKS-NRPS core as well as <italic toggle="yes">angF</italic>, encoding an acyl-CoA/acyl-ACP dehydrogenase. Therefore, it is somewhat likely the <italic toggle="yes">ang</italic> BGC only consists of the biosynthetic core <italic toggle="yes">angA-angE</italic> and <italic toggle="yes">angF</italic> or also includes the flanking genes <italic toggle="yes">ang1-ang6</italic> upstream and <italic toggle="yes">ang7-ang8</italic> downstream the core region that might also perform relevant functions for angiolam biosynthesis.</p><p>BLAST searches of <italic toggle="yes">angA-angE</italic> against draft genomes (Sebastian Walesch, unpublished data) of the known angiolam-producing strains <italic toggle="yes">Pyxidicoccus fallax</italic> An d30 (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>) and <italic toggle="yes">P. fallax</italic> An d48 (<xref rid="B26" ref-type="bibr">26</xref>) indicated the presence of the BGC but divided into several contigs due to poor DNA sequence quality. Furthermore, parts of the biosynthetic machinery, divided into at least two contigs, could be observed in the deposited genomes of <italic toggle="yes">P. fallax</italic> An d47 (GCA_012933655.1) and <italic toggle="yes">P. fallax</italic> CA059B (GCA_013155555.1).</p><p>In order to verify the compound-to-BGC assignment, the angiolam biosynthetic gene cluster was inactivated via single crossover plasmid insertion. As genetic manipulation of both new angiolam-producing strains MCy12716 and MCy12733 could not be achieved, the inactivation was performed in the genetically amenable producer <italic toggle="yes">P. fallax</italic> An d48 (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>) for which single crossover inactivation has already been shown to be achievable. A pCR2.1-TOPO-derived vector carrying a 1 kb homology fragment of the <italic toggle="yes">angB</italic> gene was integrated into the <italic toggle="yes">angB</italic> gene on the <italic toggle="yes">P. fallax</italic> An d48 chromosome. A mutant strain was selected on YM agar, supplemented with 50 &#x000b5;g/mL kanamycin. It was then cultivated for gDNA extraction and subsequent verification via PCR (Fig. S9), as well as to generate crude extracts to monitor angiolam production.</p><p>The single cross-over inactivation abolished the production of angiolam A (1, <xref rid="F4" ref-type="fig">Fig. 4</xref>). Furthermore, no other angiolam derivative could be detected. This finding confirmed that <italic toggle="yes">ang</italic> BGC is the locus responsible for the production of the angiolam compound family.</p><fig position="float" fig-type="figure" id="F4"><label>Fig 4</label><caption><p>Analytical verification of the angiolam BGC assignment. UHPLC MS extracted ion chromatogramEIC traces of angiolams A, B, and C (B, D; blue, red, and green) as [M-H<sub>2</sub>O + H]<sup>+</sup> ions (1, 570.379 Da and 3, 572.395 Da) and as [M + H]<sup>+</sup> ions (2, 586.374 Da) in the wild type (<bold>A and B</bold>) and in the angB single cross-over inactivation mutant (<bold>C and D</bold>) crude extracts. Gray traces represent the corresponding base peak chromatograms (BPC). Intensity scale in D is magnified 100-fold. EIC traces in panel D are stacked for a better overview.</p></caption><graphic xlink:href="spectrum.03689-23.f004" position="float"/></fig><p>Our biosynthetic findings agree with previous feeding experiments, revealing the biogenesis of angiolam A to comprise seven propionate equivalents, five acetate equivalents, and <sc>l</sc>-valine (<xref rid="B24" ref-type="bibr">24</xref>). According to predictions by antiSMASH (<xref rid="B32" ref-type="bibr">32</xref>) and domain fingerprints (<xref rid="B33" ref-type="bibr">33</xref>), the acyltransferases (ATs) of the loading module and modules 1, 3, 6, 10, 11, and 12 selectively incorporate methylmalonyl-CoA and the ATs of modules 2, 4, 5, 7, and 9 are selective for malonyl-CoA (Table S22; Fig. S4). The adenylation (A) domain of module 8 incorporates glycine or alanine, according to antiSMASH (Table S22). Analysis of the ketoreductase (KR), dehydratase (DH), and enoylreductase (ER) domains was done by antiSMASH, according to fingerprints (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>) or based on a hidden Markov model (<xref rid="B36" ref-type="bibr">36</xref>) (Table S23; Fig. S5 to S7). Deviations from the &#x0201c;colinearity rule&#x0201d; can be explained by inactive ER domains in modules 2 and 12, an inactive KR domain in module 10, a missing KR domain, as well as an inactive DH domain in module 7. Moreover, the <italic toggle="yes">in silico</italic> predictions of the stereochemistry based on KR, DH, and ER domains matched the actual stereochemistry of angiolam A.</p><p>An unusual feature of angiolam A is the distal alkene moiety, an altogether rare structural feature in natural products (<xref rid="B37" ref-type="bibr">37</xref>). The terminal alkenes in curacin A and tautomycetin are formed while or after they are released from the respective megasynthase (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Similar to angiolam A, the alkene starter in haliangicin A is part of its starter unit and is formed by the acyl-CoA dehydrogenase HliR through a &#x003b3;,&#x003b4;-dehydrogenation of 2-methylpent-2-enoyl-CoA (<xref rid="B40" ref-type="bibr">40</xref>). Based on this finding, a possible explanation for the distal alkene moiety of angiolam A could be a dehydrogenation of the methylmalonyl-CoA-derived starter unit to prop-2-enoyl-ACP by the acyl-CoA/acyl-ACP dehydrogenase AngF in the loading module (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). However, dehydrogenation to form the distal alkene is also possible later, during or after the assembly line biosynthesis.</p><fig position="float" fig-type="figure" id="F5"><label>Fig 5</label><caption><p><italic toggle="yes">In silico</italic> biosynthesis of angiolam A. (<bold>A</bold>) Scheme of the proposed angiolam BGC and the angiolam biosynthesis model by its megasynthase. (<bold>B</bold>) Potential biosynthesis of the prop-2-enoyl-ACP starter unit via dehydrogenation of propanoyl-ACP by AngF (arrows, genes; circles, domains; A, adenylation; ACP/PCP, acyl-/peptidyl-carrier protein; AT, acyl transferase; C, condensation; DH, dehydratase; ER, enoylreductase; KR, ketoreductase; KS, ketosynthase; and TE, thioesterase).</p></caption><graphic xlink:href="spectrum.03689-23.f005" position="float"/></fig><p>Following the incorporation of the starter unit, angiolam A undergoes seven PKS-derived elongation steps including the incorporation of four malonyl-CoA and three methylmalonyl-CoA extender units with varying oxidation states, based on the respective reductive loops. Next, <sc>l</sc>-alanine is incorporated by the NRPS module 8. This is followed by four further PKS-derived elongation steps of one malonyl-CoA and three methylmalonyl-CoA extender units to form the angiolam A backbone. Finally, the fully elongated intermediate is cyclized and released from the PKS-NRPS machinery by the thioesterase domain in module 12 (<xref rid="F5" ref-type="fig">Fig. 5A</xref>).</p><p>The likely explanations for the structural differences observed in angiolams B and C are incomplete reduction by the KR domain in module 2 and dehydrogenation reactions at the end of the angiolam side chain, respectively. The observation of the ethyl residues in modules 11 and 12 in angiolams D and F is more surprising. As feeding experiments with L-methionine-(methyl <sup>13</sup>C) did not result in mass shifts (Fig. S8), a SAM-dependent methylation of the respective methyl residues seemed unlikely. Therefore, we concluded that these ethyl residues originate from ethylmalonyl-CoA extender units and are incorporated by AT domains with broader substrate specificities. A prominent example of an AT domain that incorporates methylmalonyl-CoA and ethylmalonyl-CoA is the AT domain of module 5 of the monensin biosynthesic gene cluster (<xref rid="B41" ref-type="bibr">41</xref>). Screening of the ang AT domains for the reported signature sequence RiDVV (<xref rid="B41" ref-type="bibr">41</xref>) revealed that not only modules 11 and 12 but also modules 3, 6, and 10 might have the capacity to accept ethylmalonyl-CoA as an extender unit (Fig. S4), leading to the observed natural structural diversity of angiolams. We reason that this also explains the finding of angiolams D and F as mixtures of several components. However, the reasons for the increased incorporation of ethylmalonyl-CoA by modules 11 and 12 in comparison to the others remain elusive. Interestingly, AT domains in modules 2, 5, 6, 7, and 8 in the epothilone BGC in <italic toggle="yes">Sorangium cellulosum</italic> So ce90 (<xref rid="B42" ref-type="bibr">42</xref>) also display the signature sequence RiDVV. So far, there is only one report about an epothilone derivative with an ethyl residue, putatively incorporated by one of these AT domains (<xref rid="B43" ref-type="bibr">43</xref>), indicating that this signature sequence might point toward AT domains that accept either methyl- or ethylmalonyl CoA as their substrate. However, the prioritization of the substrate seems to depend on other parameters like other sequence motifs within the AT domains or its three-dimensional structure, KS domain substrate specificities, or precursor supply.</p><p>The importance of precursor supply for the incorporation of ethylmalonyl-CoA is demonstrated by the increased production of angiolams D and F in cultivations with added <sc>l</sc>-valine, as it serves as a precursor for ethylmalonyl-CoA (<xref rid="B44" ref-type="bibr">44</xref>). As <sc>l</sc>-valine can also be a precursor of methylmalonyl-CoA (<xref rid="B44" ref-type="bibr">44</xref>), feeding experiments with <sc>l</sc>-valine <sup>13</sup>C<sub>5</sub> resulted in inconclusive results (data not shown). However, the role of <sc>l</sc>-valine as a precursor for the ethylmalonyl-CoA supply in MCy12733 is further evidenced by the presence of a gene encoding a fused isobutyryl-CoA mutase located elsewhere within its genome (Tables S19 and S20). Furthermore, the addition of butyrate, a possible intermediate in the pathway from <sc>l</sc>-valine to ethylmalonyl-CoA, also increased the production of angiolams D and F (Table S24) reinforcing this hypothesis.</p></sec><sec id="s2-4"><title>Antiparasitic activities</title><p>Based on the antiparasitic bioactivity of the crude extract of MCy12716, angiolams A (1), B (2), C (3), D (4), and F (5) were tested for their <italic toggle="yes">in vitro</italic> activities against the following protozoan parasites: <italic toggle="yes">Trypanosoma brucei rhodesiense</italic> (STIB 900) bloodstream forms, <italic toggle="yes">Trypanosoma cruzi</italic> (Tulahuen C4) amastigotes, <italic toggle="yes">Leishmania donovani</italic> (MHOM/ET/67/L82) axenic amastigotes, and <italic toggle="yes">Plasmodium falciparum</italic> (NF54) proliferative erythrocytic stages. In parallel, the cytotoxicity of these compounds in rat skeletal myoblasts (L-6 cells) was determined in order to obtain an initial assessment of their selectivity. The results are reported in <xref rid="T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="T1"><label>TABLE 1</label><caption><p><italic toggle="yes">In vitro</italic> activity of compounds 1&#x02013;5 against <italic toggle="yes">L. donovani</italic> (MHOM-ET-67/L82) axenic amastigotes, <italic toggle="yes">P. falciparum</italic> (NF54), <italic toggle="yes">T. b. rhodesiense</italic> (STIB 900), <italic toggle="yes">T. cruzi</italic> (Tulahuen C4), and cytotoxicity in L6 cells</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="2" colspan="1">ID No</th><th align="center" valign="bottom" colspan="2" rowspan="1">
<italic toggle="yes">T. b. rhodesiense</italic>
</th><th align="center" valign="bottom" colspan="2" rowspan="1">
<italic toggle="yes">T. cruzi</italic>
</th><th align="center" valign="bottom" colspan="2" rowspan="1">
<italic toggle="yes">L. donovani</italic>
</th><th align="center" valign="bottom" colspan="2" rowspan="1">
<italic toggle="yes">P. falciparum</italic>
</th><th align="left" valign="bottom" colspan="1" rowspan="1">Cytotoxicity in L6 cells</th></tr><tr><th align="center" valign="top" colspan="1" rowspan="1">IC<sub>50</sub><italic toggle="yes"><xref rid="T1_FN1" ref-type="table-fn"><sup>a</sup></xref></italic> (&#x000b5;M)</th><th align="center" valign="top" colspan="1" rowspan="1">SI<italic toggle="yes"><xref rid="T1_FN2" ref-type="table-fn"><sup>b</sup></xref></italic></th><th align="center" valign="top" colspan="1" rowspan="1">IC<sub>50</sub><italic toggle="yes"><xref rid="T1_FN1" ref-type="table-fn"><sup>a</sup></xref></italic> (&#x000b5;M)</th><th align="center" valign="top" colspan="1" rowspan="1">SI<italic toggle="yes"><xref rid="T1_FN2" ref-type="table-fn"><sup>b</sup></xref></italic></th><th align="center" valign="top" colspan="1" rowspan="1">IC<sub>50</sub><italic toggle="yes"><xref rid="T1_FN1" ref-type="table-fn"><sup>a</sup></xref></italic> (&#x000b5;M)</th><th align="center" valign="top" colspan="1" rowspan="1">SI<italic toggle="yes"><xref rid="T1_FN2" ref-type="table-fn"><sup>b</sup></xref></italic></th><th align="center" valign="top" colspan="1" rowspan="1">IC<sub>50</sub><italic toggle="yes"><xref rid="T1_FN1" ref-type="table-fn"><sup>a</sup></xref></italic> (&#x000b5;M)</th><th align="center" valign="top" colspan="1" rowspan="1">SI<italic toggle="yes"><xref rid="T1_FN2" ref-type="table-fn"><sup>b</sup></xref></italic></th><th align="center" valign="top" colspan="1" rowspan="1">IC<sub>50</sub><italic toggle="yes"><xref rid="T1_FN1" ref-type="table-fn"><sup>a</sup></xref></italic> (&#x000b5;M)</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">Angiolam A (1)</td><td align="center" valign="top" colspan="1" rowspan="1">1.5 &#x000b1; 0.6</td><td align="center" valign="top" colspan="1" rowspan="1">63.2</td><td align="center" valign="top" colspan="1" rowspan="1">12.9 &#x000b1; 5.3</td><td align="center" valign="top" colspan="1" rowspan="1">7.3</td><td align="center" valign="top" colspan="1" rowspan="1">16.7 &#x000b1; 7.3</td><td align="center" valign="top" colspan="1" rowspan="1">5.62</td><td align="center" valign="top" colspan="1" rowspan="1">2.7 &#x000b1; 0.5</td><td align="center" valign="top" colspan="1" rowspan="1">34.9</td><td align="center" valign="top" colspan="1" rowspan="1">94.0 &#x000b1; 23.7</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Angiolam B (2)</td><td align="center" valign="top" colspan="1" rowspan="1">6.3 &#x000b1; 1.0</td><td align="center" valign="top" colspan="1" rowspan="1">4.4</td><td align="center" valign="top" colspan="1" rowspan="1">30.4 &#x000b1; 10.0</td><td align="center" valign="top" colspan="1" rowspan="1">0.9</td><td align="center" valign="top" colspan="1" rowspan="1">6.6 &#x000b1; 1.9</td><td align="center" valign="top" colspan="1" rowspan="1">4.22</td><td align="center" valign="top" colspan="1" rowspan="1">0.3 &#x000b1; 0.1</td><td align="center" valign="top" colspan="1" rowspan="1">91.6</td><td align="center" valign="top" colspan="1" rowspan="1">27.8 &#x000b1; 2.0</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Angiolam C (3)</td><td align="center" valign="top" colspan="1" rowspan="1">4.5 &#x000b1; 0.4</td><td align="center" valign="top" colspan="1" rowspan="1">6.8</td><td align="center" valign="top" colspan="1" rowspan="1">34.0 &#x000b1; 11.6</td><td align="center" valign="top" colspan="1" rowspan="1">0.9</td><td align="center" valign="top" colspan="1" rowspan="1">15.4 &#x000b1; 2.3</td><td align="center" valign="top" colspan="1" rowspan="1">1.99</td><td align="center" valign="top" colspan="1" rowspan="1">0.6 &#x000b1; 0.4</td><td align="center" valign="top" colspan="1" rowspan="1">53.7</td><td align="center" valign="top" colspan="1" rowspan="1">30.6 &#x000b1; 2.3</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Angiolam D (4)</td><td align="center" valign="top" colspan="1" rowspan="1">4.7 &#x000b1; 1.9</td><td align="center" valign="top" colspan="1" rowspan="1">6.0</td><td align="center" valign="top" colspan="1" rowspan="1">6.5 &#x000b1; 2.2</td><td align="center" valign="top" colspan="1" rowspan="1">4.3</td><td align="center" valign="top" colspan="1" rowspan="1">8.2 &#x000b1; 4.5</td><td align="center" valign="top" colspan="1" rowspan="1">3.38</td><td align="center" valign="top" colspan="1" rowspan="1">0.8 &#x000b1; 0.6</td><td align="center" valign="top" colspan="1" rowspan="1">37.1</td><td align="center" valign="top" colspan="1" rowspan="1">27.8 &#x000b1; 3.7</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Angiolam F (5)</td><td align="center" valign="top" colspan="1" rowspan="1">25.0 &#x000b1; 1.4</td><td align="center" valign="top" colspan="1" rowspan="1">2.0</td><td align="center" valign="top" colspan="1" rowspan="1">24.4 &#x000b1; 5.0</td><td align="center" valign="top" colspan="1" rowspan="1">2.1</td><td align="center" valign="top" colspan="1" rowspan="1">17.6 &#x000b1; 2.1</td><td align="center" valign="top" colspan="1" rowspan="1">2.83</td><td align="center" valign="top" colspan="1" rowspan="1">1.3 &#x000b1; 0.6</td><td align="center" valign="top" colspan="1" rowspan="1">37.4</td><td align="center" valign="top" colspan="1" rowspan="1">49.9 &#x000b1; 21.6</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Positive control</td><td align="center" valign="top" colspan="1" rowspan="1">0.02<xref rid="T1_FN3" ref-type="table-fn"><sup><italic toggle="yes">c</italic></sup></xref></td><td align="center" valign="top" colspan="1" rowspan="1"/><td align="center" valign="top" colspan="1" rowspan="1">2.47<xref rid="T1_FN4" ref-type="table-fn"><sup><italic toggle="yes">d</italic></sup></xref></td><td align="center" valign="top" colspan="1" rowspan="1"/><td align="center" valign="top" colspan="1" rowspan="1">0.53<italic toggle="yes"><xref rid="T1_FN5" ref-type="table-fn"><sup>e</sup></xref></italic></td><td align="center" valign="top" colspan="1" rowspan="1"/><td align="center" valign="top" colspan="1" rowspan="1">0.004<xref rid="T1_FN6" ref-type="table-fn"><sup><italic toggle="yes">f</italic></sup></xref></td><td align="center" valign="top" colspan="1" rowspan="1"/><td align="center" valign="top" colspan="1" rowspan="1">0.02<xref rid="T1_FN7" ref-type="table-fn"><sup><italic toggle="yes">g</italic></sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1"><label>
<sup>
<italic toggle="yes">a</italic>
</sup>
</label><p>The IC<sub>50</sub>s are mean values from at least three independent replicates &#x000b1; standard deviation.</p></fn><fn id="T1_FN2"><label>
<sup>
<italic toggle="yes">b</italic>
</sup>
</label><p>Selectivity index (SI): IC<sub>50</sub> in L6 cells divided by IC<sub>50</sub> in the titled parasitic strain.</p></fn><fn id="T1_FN3"><label>
<sup>
<italic toggle="yes">c</italic>
</sup>
</label><p>Melarsoprol.</p></fn><fn id="T1_FN4"><label>
<sup>
<italic toggle="yes">d</italic>
</sup>
</label><p>Benznidazole.</p></fn><fn id="T1_FN5"><label>
<sup>
<italic toggle="yes">e</italic>
</sup>
</label><p>Miltefosine.</p></fn><fn id="T1_FN6"><label>
<sup>
<italic toggle="yes">f</italic>
</sup>
</label><p>Chloroquine.</p></fn><fn id="T1_FN7"><label>
<sup>
<italic toggle="yes">g</italic>
</sup>
</label><p>Podophyllotoxin.</p></fn></table-wrap-foot></table-wrap><sec id="s2-4-1"><title>Activity against trypanosomatids</title><p>Comparing the activity of different angiolam congeners against <italic toggle="yes">Trypanosoma brucei rhodesiense</italic>, there is a clear matching between the antitrypanosomal activity and selectivity (A &#x0003e; C &#x0003e; D1 &#x0003e;B &#x0003e; F). Angiolam A showed the highest activity (IC<sub>50</sub> of 1.5 &#x000b5;M) toward <italic toggle="yes">T. brucei</italic> as well as preferential selectivity across all the three trypansomatids. Its trypanocidal activity is comparable to that previously described for Macyranone A, a peptide-epoxyketone isolated from another myxobacterial strain <italic toggle="yes">Cystobacter fuscus</italic> MCy9118 (<xref rid="B11" ref-type="bibr">11</xref>). Angiolams B, C, and D showed similar activity and toxicity profiles against <italic toggle="yes">T. b. rhodesiense</italic> (IC<sub>50</sub> range: 4.5&#x02013;6.3 &#x000b5;M, SI: 4.4&#x02013;6.8), while angiolam F was the least active and most cytotoxic.</p><p><italic toggle="yes">Trypanosoma cruzi</italic> was the least sensitive parasite (IC<sub>50</sub>: 6.6&#x02013;34.0 &#x000b5;M) with unfavorable selectivities displayed by most of the tested compounds (angiolams B, C, and F) due to their relatively high cytotoxicity (SI &#x02264; 2.1). Although both <italic toggle="yes">T. brucei</italic> and <italic toggle="yes">T. cruzi</italic> are trypansomatids, however, the lack of overlapping activity is not unusual (<xref rid="B45" ref-type="bibr">45</xref>). This could be partially explained by the intracellular nature of the parasite (<xref rid="B46" ref-type="bibr">46</xref>). Nevertheless, angiolam D was found to be the most active (IC<sub>50</sub>: 6.5 &#x000b5;M), with twofold higher activity with respect to angiolam A. This could be attributed to the CH<sub>3</sub> extension at C-33 or C-34, which, on the other hand, diminished the selectivity.</p><p>Angiolams exhibited moderate to low activity (IC<sub>50</sub>: 6.6&#x02013;17.6 &#x000b5;M) and unsatisfactory selectivity (selectivity indices of 2&#x02013;6) toward <italic toggle="yes">L. donovani</italic> axenic amastigotes. Angiolam B has shown the highest activity (IC<sub>50</sub>: 6.6 &#x000b5;M), though 20-fold weaker than its displayed activity against <italic toggle="yes">P. falciparum</italic>, followed by angiolam D (IC<sub>50</sub>: 8.2 &#x000b5;M). Angiolams A, C, and F showed comparable activities (IC<sub>50</sub>: 15.4&#x02013;17.6 &#x000b5;M), with angiolam C being the most cytotoxic.</p></sec><sec id="s2-4-2"><title>Activity against <italic toggle="yes">Plasmodium falciparum</italic></title><p>The <italic toggle="yes">in vitro</italic> activity of angiolams against the erythrocytic stages of the <italic toggle="yes">P. falciparum</italic> strain NF54 was the most promising compared to the other parasites tested. Angiolams B, C, and D showed activity in submicromolar concentrations (IC<sub>50</sub>: 0.3&#x02013;0.8 &#x000b5;M) with high selectivities (SI &#x02265; 30). The most promising compound of this series was angiolam B exhibiting submicromolar activity (IC<sub>50</sub>: 0.3 &#x000b5;M) and highest selectivity (SI: 91.6). We assume that this could be due to the oxidation of C-5 that has an augmenting effect on both activity and selectivity. Angiolams D and F showed IC<sub>50</sub> values of 0.8 and 1.3 &#x000b5;M, respectively. The presence of two ethyl groups in angiolam F may have contributed to the reduced activity; however, this substitution did not show an effect on the selectivity (SI 37 for both D and F). Unlike its antitrypanosomal activity, angiolam A showed the least antiplasmodial activity and selectivity among the tested angiolam derivatives.</p></sec></sec><sec id="s2-5"><title>Conclusion and outlook</title><p>This study demonstrates the prospects of a regional sampling campaign to bring forward new myxobacterial natural product producers, in combination with screening efforts that go beyond antibacterial or cytotoxic activities. The uncovering of new producing strains with unexpected bioactivities reinvigorated the interest in angiolam almost 40 years after it was first reported as an antibiotic (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). This interest subsequently led to the characterization of several novel angiolam derivatives with improved bioactivities against <italic toggle="yes">P. falciparum</italic>. It also initiated the elucidation of the underlying biosynthesis, including a potentially rare enzymatic dehydrogenation of the starter unit. Moreover, our present data highlight the potential of the angiolam scaffold as a starting point for the development of novel drugs with anti-parasitic bioactivities. This view is supported by the promising selectivity index of most angiolam derivatives against <italic toggle="yes">P. falciparum</italic> in combination with the reported tolerability of angiolam A in mice as well as the availability of a total synthesis route (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B31" ref-type="bibr">31</xref>).</p><p>Taken together, this study illustrates the opportunities of reinvestigating &#x0201c;old&#x0201d; natural products with improved analytical and computational resources at hand. Given the energetic effort that microorganisms put into the biosynthesis of these compounds, it is likely that the competitive advantage conveyed by these natural products comes with additional biological activities awaiting their future discovery through suitable bioassays.</p></sec></sec><sec sec-type="materials|methods" id="s3"><title>MATERIALS AND METHODS</title><sec id="s3-1"><title>Isolation of myxobacteria</title><p>Both myxobacterial strains MCy12716 and MCy12733 originated from the citizen-science campaign &#x0201c;Sample das Saarland,&#x0201d; a regional project initiated in 2017 that aims to discover novel antibiotics and new anti-infectives from local samples. The first strain MCy12716 was isolated in March 2019 based on the standard bacterial predation method using <italic toggle="yes">Escherichia coli</italic>. This strain came from pond soil sediments collected in the summer of 2018 (03 June) in an area between Karlsbrunn and Ludweiler, Germany (coordinates: 49.20153847434484,6.800456559291888). On the other hand, the second myxobacterium MCy12733 was isolated after a month (April 2019) but from a soil sample with decaying leaves collected on 09 August 2018 at A&#x000df;weiler, Germany (GPS coordinates: 49.2189122,7.192166499999985). Its discovery was also based on <italic toggle="yes">E. coli</italic> lysis, formation of swarming colony, and development of fruiting bodies on Stan-21 mineral salt agar medium. Axenic cultures were achieved by repeated transferring of the swarm cells taken from the colony margin and by maintaining in VY/2 agar, which supports growth developmental stages, including swarming and fruiting body formation. These two myxobacterial isolates were identified by 16S rRNA gene amplification using universal 27F and 1492R primers. Their closest related type strains were determined by BLAST search and phylogenetic analysis.</p></sec><sec id="s3-2"><title>Fermentation of myxobacteria for analytical purposes</title><p>Cultures for analytical purposes were grown in 300 mL shake flasks containing 50 or 100 mL of the respective fermentation medium inoculated with 2% (vol/vol) pre-culture. The medium was supplemented with 4% (vol/vol) of a sterile aqueous solution of XAD-16 adsorber resin (Sigma Aldrich) to bind secondary metabolites in the culture medium. After 7&#x02013;10 days of cultivation, the culture is pelleted in 50 mL falcon tubes in an Eppendorf centrifuge 5804R at 8,288 &#x000d7; <italic toggle="yes">g</italic> and 4&#x000b0;C for 10 min. The pellet is then stored at &#x02212;20&#x000b0;C until further use.</p></sec><sec id="s3-3"><title>Feeding experiments with stable isotope-labeled precursors</title><p>Feeding experiments were performed in 100 mL shake flasks containing 20 mL of the respective fermentation medium inoculated with 2.5% (vol/vol) SBCy413 pre-culture. At 12-, 24-, 36-, 48-, and 60-h post-inoculation, 200 &#x000b5;L of an aqueous solution of 50 mM L-alanine <sup>15</sup>N (Sigma Aldrich) or L-methionine-(methyl <sup>13</sup>C) (Cambridge Isotope Laboratories) was added to the cultures. After another 12 h of cultivation, 5% (vol/vol) sterile aqueous solution of XAD-16 adsorber resin was added to the cultures. After approximately 4 days of cultivation, the culture is pelleted in 50 mL falcon tubes in an Eppendorf centrifuge 5804R at 8,288 &#x000d7; <italic toggle="yes">g</italic> and 4&#x000b0;C for 10 min. The pellet is then stored at &#x02212;20&#x000b0;C until further use.</p></sec><sec id="s3-4"><title>Large-scale fermentation for compound purification</title><p>Pre-cultures of MCy12733 were cultivated in 300 mL shake flasks containing 100 mL of the respective fermentation medium at 30&#x000b0;C and 180 rpm for 5 days. These pre-cultures are used to inoculate [5% (vol/vol) inoculum) 6 &#x000d7; 2 L of the respective fermentation medium, supplemented with 5% (vol/vol) of a sterile aqueous solution of XAD-16 adsorber resin in 5 L shaking flasks. Fermentation was performed at 30&#x000b0;C and 170 rpm for 21 days. Afterward, the combined cultures were pelleted with an Avanti J-26 XP centrifuge, equipped with a JLA-8.1 rotor (Beckman Coulter) at 11,978 &#x000d7; <italic toggle="yes">g</italic> and 4&#x000b0;C for 15 min. The pellet was then frozen, freeze-dried, and stored at &#x02212;20&#x000b0;C until further use.</p></sec><sec id="s3-5"><title>Preparation of gDNA</title><p>Genomic DNA of <italic toggle="yes">P. fallax</italic> An d48 for cloning purposes and <italic toggle="yes">P. fallax</italic> An d48-AngKO to verify the integration of pTOPO-AngKO within angB was isolated using the Puregene Core Kit A (Qiagen) or the DNeasy UltraClean Microbial Kit (Qiagen), according to the manufacturer&#x02019;s instructions.</p><p>To isolate the gDNA of MCy12716 and MCy12733 for Illumina sequencing, standard phenol-chloroform extraction was used.</p></sec><sec id="s3-6"><title>Whole-genome sequencing</title><p>The genome sequence of strain MCy12733 was acquired using Illumina technology to give 88 assembled contigs with a total sequence length of 13.77 Mbp.</p></sec><sec id="s3-7"><title>PCR amplification</title><p>Amplification of a genetic region in <italic toggle="yes">angB</italic> for gene disruption by single cross-over and PCRs to verify the integration of the plasmid into the angiolam BGC in <italic toggle="yes">P. fallax</italic> An d48 were done with the Phusion High-Fidelity polymerase (Thermo Scientific). All PCR amplifications were performed in a MasterCycler Pro S (Eppendorf). The success of PCR amplifications was checked by agarose gel electrophoresis. Bands of PCR products for cloning purposes were cut out and purified using the Nucleospin Gel and PCR Clean-Up Kit (Macherey-Nagel). Further information about PCR mixes and cycler protocols can be found in the supplemental material (Tables S5 to S8).</p></sec><sec id="s3-8"><title>Restriction enzyme digestion protocols</title><p>Restriction enzyme digestions for cloning purposes were performed in volumes of 20 &#x000b5;L with 350 ng PCR product or 1.2 &#x000b5;g cyclized pCR2.1-TOPO vector, respectively. Aqueous solutions of the PCR product or the cyclized pCR2.1-TOPO vector were mixed with 2 &#x000b5;L of 10&#x000d7; EcoRI buffer and 1 &#x000b5;L of EcoRI (10 U/&#x000b5;L, Thermo Scientific) and incubated at 37&#x000b0;C. After 2 h, 1 &#x000b5;L of FastAP (1 U/&#x000b5;L, Thermo Scientific) was added to the reaction mixture of the vector to dephosphorylate its ends. All digestion reactions were stopped after 3 h of incubation, and the resulting products were subsequently purified, using the Nucleospin Gel and PCR Clean-Up Kit (Macherey-Nagel).</p><p>Control digestions to verify the success of cloning were performed in volumes of 10 &#x000b5;L with approximately 1 &#x000b5;g plasmid. Aqueous solutions of cloned plasmid were mixed with 1 &#x000b5;L of Tango buffer (Thermo Scientific) and 0.5 &#x000b5;L of NcoI (10 U/ &#x000b5;L, Thermo Scientific) or 0.5 &#x000b5;L of NaeI (10 U/ &#x000b5;L, Thermo Scientific) and incubated at 37&#x000b0;C for 2 h. Successful cloning was verified by agarose gel electrophoresis and sequencing of the obtained plasmid.</p></sec><sec id="s3-9"><title>Ligation protocol</title><p>Ligation of DNA was carried out with ~50 ng vector and a fivefold molar excess of insert. Vector and insert were mixed with 2 &#x000b5;L of 10&#x000d7; T4 buffer, 1 &#x000b5;L T4 ligase (5 U/ &#x000b5;L; Thermo Fisher Scientific), and autoclaved Milli-Q water to a final volume of 20 &#x000b5;L. Reactions were incubated at 25&#x000b0;C for 4 h or at 16&#x000b0;C overnight and subsequently electroporated into <italic toggle="yes">E. coli</italic> HS996.</p></sec><sec id="s3-10"><title>Transformation of <italic toggle="yes">E. coli</italic> HS996</title><p>One milliliter of an overnight culture of <italic toggle="yes">E. coli</italic> cells in LB was inoculated into 20 mL of LB medium and grown at 37&#x000b0;C until it reached an OD<sub>600</sub> of 0.6. The cells were centrifuged at 11,467 &#x000d7; <italic toggle="yes">g</italic> and 4&#x000b0;C (HIMAC CT15RE, Koki Holdings Co.) for 90 s in 2 mL Eppendorf tubes. The cell pellet was washed twice with ice-cold sterile MQ water, first with 1,000 &#x000b5;L, then with 800 &#x000b5;L. After the washing procedure, <italic toggle="yes">E. coli</italic> cells were resuspended in 50 &#x000b5;L ice-cold sterile MQ water, kept on ice, and subsequently used for electroporation.</p><p><italic toggle="yes">E. coli</italic> cells were mixed with 3&#x02013;5 &#x000b5;L ligation product or 100 ng plasmid and transferred to an electroporation cuvette. Electroporation was carried out at 25 &#x000b5;F, 200 &#x003a9;, and 1,250 V. The electroporation product was immediately mixed with 1 mL LB medium and incubated in 2 mL Eppendorf tubes at 37&#x000b0;C and 750 rpm for 45 min. Incubated cells were spread on LB-agar plates containing 50 &#x000b5;g/mL kanamycin and incubated overnight at 37&#x000b0;C. Around 10 clones were picked and cultivated in 5 mL LB containing 50 &#x000b5;g/mL kanamycin for subsequent plasmid isolation.</p></sec><sec id="s3-11"><title>Plasmid isolation</title><p>Plasmid isolation for cloning purposes or transformation into <italic toggle="yes">P. fallax</italic> An d48 was performed with the GeneJET Miniprep Kit (Thermo Scientific). Plasmid isolation for control digestions to verify successful cloning was done with standard alkaline lysis (<xref rid="B47" ref-type="bibr">47</xref>).</p></sec><sec id="s3-12"><title>Transformation into <italic toggle="yes">P. fallax</italic> An d48</title><p>Electroporation of <italic toggle="yes">P. fallax</italic> An d48 was adapted from Panter et al. (<xref rid="B27" ref-type="bibr">27</xref>). Two milliliters of an An d48 culture in YM medium at OD<sub>600</sub> of approximately 0.7 were centrifuged at 11,467 &#x000d7; <italic toggle="yes">g</italic> (HIMAC CT15RE, Koki Holdings Co.) for 2 min. The pelleted cells were washed twice with sterile MQ water, first with 1,000 &#x000b5;L, then with 800 &#x000b5;L. After the washing procedure, the cells were resuspended in 50 &#x000b5;L sterile MQ water, mixed with 5 &#x000b5;L of plasmid solution at a concentration of 0.3&#x02013;0.4 &#x003bc;g/&#x003bc;L, and moved to an electroporation cuvette. Electroporation was performed at 675 V, 400 &#x003a9;, 25 &#x000b5;F, and 1 mm cuvette width. Afterward, the cells were flushed out with 1 mL YM medium and moved to a 2 mL Eppendorf tube with a small hole in the lid. After incubation at 30&#x000b0;C and 1,000 rpm for 5 h, the cell suspension was mixed with 3 mL YM soft agar, containing 50 &#x000b5;g/mL kanamycin, and the mixture was distributed on a YM agar plate containing 50 &#x000b5;g/mL kanamycin. Slightly red, spherical transformants could be observed after 10&#x02013;14 days of cultivation at 30&#x000b0;C.</p></sec><sec id="s3-13"><title>Crude extract generation for analytical purposes</title><p>Frozen or freeze-dried pellets from small-scale cultivations were suspended in 40 or 80 mL methanol and stirred at 250 rpm at room temperature for 2 h. The supernatant was decanted into a round flask through a 125-&#x000b5;m folded filter. The solvent and potential residual water were removed on a rotary evaporator with a water bath temperature of 40&#x000b0;C at appropriate pressures. The dried extract was dissolved/resuspended in 1,100 &#x000b5;L MeOH/100 mL cultivation volume. The crude extract was stored at &#x02212;20&#x000b0;C until further analysis. For the purpose of UHPLC-hrMS analysis, the crude extract was diluted 1:5 with methanol and centrifuged at 21,500 &#x000d7; <italic toggle="yes">g</italic> and 4&#x000b0;C (HIMAC CT15RE, Koki Holdings Co.) for 5 min to remove residual insolubilities such as salts, cell debris, and XAD fragments.</p></sec><sec id="s3-14"><title>Standardized UHPLC-MS conditions</title><p>UPLC-hrMS analysis was performed on a Dionex (Germering, Germany) Ultimate 3000 RSLC system using a Waters (Eschborn, Germany) BEH C18 column (50 &#x000d7; 2.1 mm, 1.7 &#x000b5;m) equipped with a Waters VanGuard BEH C18 1.7 &#x000b5;m guard column. Separation of 1 &#x000b5;L sample was achieved by a linear gradient from (A) H<sub>2</sub>O + 0.1% formic acid (FA) to (B) ACN + 0.1% FA at a flow rate of 600 &#x000b5;L/min and a column temperature of 45&#x000b0;C. Gradient conditions for crude extract analysis were as follows: 0&#x02013;0.5 min, 5% B; 0.5&#x02013;18.5 min, 5%&#x02013;95% B; 18.5&#x02013;20.5 min, 95% B; 20.5&#x02013;21 min, 95%&#x02013;5% B; and 21&#x02013;22.5 min, 5% B. Following gradient conditions were applied to monitor angiolams during purification: 0&#x02013;0.5 min, 5% B; 0.5&#x02013;9.5 min, 5%&#x02013;95% B; 9.5&#x02013;10.5 min, 95% B; 10.5&#x02013;11 min, 95%&#x02013;5% B; and 11&#x02013;12.5 min, 5% B. UV spectra were recorded by a DAD in the range from 200 to 600 nm. The LC flow was split to 75 &#x000b5;L/min before entering the Bruker Daltonics maXis 4G hrToF mass spectrometer (Bremen, Germany) equipped with an Apollo II ESI source. Mass spectra were acquired in centroid mode ranging from 150 to 2,500 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> at a 2 Hz full scan rate. Mass spectrometry source parameters were set to 500 V as end plate offset; 4,000 V as capillary voltage; nebulizer gas pressure 1 bar; dry gas flow of 5 L/min; and a dry temperature of 200&#x000b0;C. Ion transfer and quadrupole settings were set to funnel RF 350 Vpp; multipole RF 400 Vpp as transfer settings and ion energy of 5 eV as well as a low mass cut of 300 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. The collision cell was set to 5.0 eV and pre-pulse storage time was set to 5 &#x003bc;s. The spectra acquisition rate was set to 2 Hz. Calibration was done automatically before every LC-MS run by injection of a sodium formate solution and calibration on the respective sodium formate clusters formed in the ESI source. All MS analyses were acquired in the presence of the lock masses (C<sub>12</sub>H<sub>19</sub>F<sub>12</sub>N<sub>3</sub>O<sub>6</sub>P<sub>3</sub>, C<sub>18</sub>H<sub>19</sub>O<sub>6</sub>N<sub>3</sub>P<sub>3</sub>F<sub>2</sub>, and C<sub>24</sub>H<sub>19</sub>F<sub>36</sub>N<sub>3</sub>O<sub>6</sub>P<sub>3</sub>), which generate the [M + H]<sup>+</sup> ions of 622.0289, 922.0098, and 1221.9906.</p></sec><sec id="s3-15"><title>Statistics-based metabolome filtering</title><p>For statistical metabolomics analysis, both the myxobacterial culture and medium blanks were incubated and extracted in triplicates as described above. Each extract was measured as a technical duplicate, giving a total number of six replicates each for the bacterial culture and medium blank extracts. T-ReX-3D molecular feature finder of MetaboScape 2022b (Bruker Daltonics, Billerica, MA, USA) was used to obtain molecular features. Detection parameters were set to an intensity threshold of 5 &#x000d7; 10<sup>3</sup> and a minimum peak length of five spectra to ensure a precursor selection that has a sufficient intensity to generate tandem MS data. Identification of bacterial features was performed with the built-in ANOVA/<italic toggle="yes">t</italic>-test routine and filtered to appearance in all six bacterial extracts and in none of the medium blank extracts. The <italic toggle="yes">t</italic>-test table was used to create a scheduled precursor list (SPL) for UHPLC-tandem MS analysis (<xref rid="B28" ref-type="bibr">28</xref>).</p></sec><sec id="s3-16"><title>Acquisition parameters for high-resolution tandem MS data</title><p>LC and MS conditions for SPL-guided MS/MS data acquisitions were kept constant according to section standardized UHPLC-hrMS conditions. MS/MS data acquisition parameters were set to exclusively fragment scheduled precursor list entries. SPL tolerance parameters for precursor ion selection were set to 0.2 min and 0.05 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> in the SPL MS/MS method. The method picked up to two precursors per cycle, applied smart exclusion after five spectra, and performed CID and MS/MS spectra acquisition time ramping. CID Energy was ramped from 35 eV for 500 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> to 45 eV for 1,000 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> and 60 eV for 2,000 <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. MS full scan acquisition rate was set to 2 Hz, and MS/MS spectra acquisition rates were ramped from 1 to 4 Hz for precursor ion intensities of 10&#x02013;1,000 kcts.</p></sec><sec id="s3-17"><title>Parameters for feature-based molecular networking</title><p>All supporting feature-based molecular networking data presented here were created based on the UHPLC-hrMS&#x000b2; chromatograms using the parameters specified in the previous section. All molecular features were obtained by Metaboscape 2022b, with the same parameters as in Statistics-based metabolome filtering, and the respective MS/MS spectra were detected by the built-in &#x0201c;extract MS/MS data&#x0201d; function. The resulting output files were exported with the built-in &#x0201c;Export for GNPS/Sirius&#x0201d; function and uploaded to the GNPS server at the University of California San Diego via FileZilla FTP upload to <ext-link xlink:href="ftp://%20ccms-ftp01.ucsd.edu" ext-link-type="ftp">ftp:// ccms-ftp01.ucsd.edu</ext-link> and all acquired SPL MS/MS spectra were used for feature-based network creation (<xref rid="B29" ref-type="bibr">29</xref>). A molecular network was created using the online workflow at GNPS. The data were filtered by removing all MS/MS peaks within &#x000b1;17 Da of the precursor <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>. MS/MS spectra were window filtered by choosing only the top six peaks in the &#x000b1;50 Da window throughout the spectrum. The data were then clustered with a parent mass tolerance of 0.02 Da and an MS/MS fragment ion tolerance of 0.02 Da to create consensus spectra. No further filtering of consensus spectra was done before spectral network creation. A network was then created where edges are filtered to have a cosine score above 0.7 and more than six matched peaks. Further edges between two nodes were kept in the network if and only if each of the nodes appeared in each other&#x02019;s respective top 10 most similar nodes (<xref rid="B29" ref-type="bibr">29</xref>). Furthermore, library search parameters were set to a cosine of 0.7 and a minimum of six matched peaks. Library searches included analogs with mass differences up to 200 Da. The data set was downloaded from the server and subsequently visualized using Cytoscape 3.9.1.</p></sec><sec id="s3-18"><title>Extraction and liquid/liquid partitioning</title><p>Extraction and liquid/liquid partitioning of cultures of MCy12733 in different production media were done with 100 mL of the respective solvents per 10 g freeze-dried pellet.</p><p>Freeze-dried pellets were extracted four times with a 1:1 mixture of methanol and acetone. For each extraction step, the suspension was stirred at 250 rpm for 30 min and decanted through glass wool and a 125-&#x000b5;m folded filter. The combined extracts were dried using a rotary evaporator at 40&#x000b0;C water bath temperature and appropriate pressures. The dried extract was then dissolved/resuspended in a 95:5 mixture of methanol and water and defatted three times with hexane. Finally, the defatted extract was partitioned three times between water and chloroform. The angiolam derivatives were retained in the chloroform phase. The chloroform phase was concentrated, moved to glass vials, dried, and stored at &#x02212;20&#x000b0;C.</p></sec><sec id="s3-19"><title>Pre-purification by reverse phase flash chromatography</title><p>Reverse phase flash chromatography was carried out using the Isolera One (Biotage). Versa Flash Spherical C18 silica 45&#x02013;75 &#x003bc;m, 70 &#x000c5; in a 25 g SNAP column (Biotage) was used as the stationary phase, and H<sub>2</sub>O (A) and MeOH (B) were used as the mobile phase. Flow rate was 25 mL/min, fractions of 45 mL were collected in glass tubes and solvent volume was measured in column volumes (CV); 1 CV = 33 mL. After equilibration of the system with 3 CV of 50% B, ~300 &#x000b5;g sample was loaded on the column using vacuum-dried iSolute beads (Biotage). The conditions were kept at 50% B for 2 CV, followed by an increase to 80% B over 30 CV, a ramp to 100% B over 5 CV, and a flushing step at 100% B for 5 CV. Fractions were pooled according to the abundance of angiolam derivatives, dried, and stored in glass vials at &#x02212;20&#x000b0;C.</p></sec><sec id="s3-20"><title>Purification of angiolams A, B, and F</title><p>Purification of angiolams A (1), B (2), and F (5), as well as a mixture of angiolam C (3) and D (4a/4b) from the respective pooled flash chromatography fractions, was carried out on the Waters Autopurifier (Eschborn, Germany) high-pressure gradient system. Separation was carried out on a Waters X-Bridge prep C-18 5 &#x000b5;m, 150 &#x000d7; 19 mm column using H<sub>2</sub>O + 0.1% FA (A) and ACN + 0.1% FA (B) as mobile phase at a flow rate of 25 mL/min. Separation was started with 5% B for 1 min, followed by a ramp to 40% B over 2 min and an increase to 70% B over 22 min. The column was then flushed with a ramp to 95% B over 2 min, brought back to 5% B within 1 min, and re-equilibrated at 5% for 2 min. Purified angiolams A (1), B (2), and F (5) were dried with a rotary evaporator, moved to glass vials, freeze-dried, and stored at &#x02212;20&#x000b0;C.</p></sec><sec id="s3-21"><title>Purification of angiolams C and D</title><p>The mixture of angiolams (3) and D (4a/4b) was separated on a Waters Prep 15 SFC System equipped with a 5 &#x000b5;m Torus Diol 130 &#x000c5; OBD Prep Column 250 &#x000d7; 19 mm (Waters) thermostated at 50&#x000b0;C. Separation was achieved by following multistep gradient of methanol as a co-solvent to the supercritical CO<sub>2</sub>. A ramp of 5%&#x02013;11% co-solvent within 1 min was followed by an increase to 17% over 18 min to separate angiolams (3) and D (4a/4b). Afterward, the column was flushed with an increase of 20% co-solvent for 1 min, the co-solvent was decreased to 5% within 0.5 min, and the system was re-equilibrated at 5% co-solvent for 2.5 min. The flow rate was set to 15 mL/min, make-up flow to 3 mL/min, and backpressure to 120 bar.</p></sec><sec id="s3-22"><title>NMR-based structure elucidation</title><p>The chemical structures of angiolam derivatives were determined via multidimensional NMR analysis. 1D and 2D NMR spectra were recorded at 500 MHz (<sup>1</sup>H) and 125 MHz (<sup>13</sup>C) or 700 MHz (<sup>1</sup>H) and 175 MHz (<sup>13</sup>C) conduction using an Avance III (Ultrashield) 500 MHz spectrometer or an Avance III (Ascend) 700 MHz spectrometer, respectively, both equipped with a cryogenically cooled triple resonance probe (Bruker Biospin Rheinstetten, Germany). All observed chemical shift values (<italic toggle="yes">&#x003b4;</italic>) are given in ppm and coupling constant values (<italic toggle="yes">J</italic>) in Hz. Standard pulse programs were used for HMBC, HSQC, and gCOSY experiments. HMBC experiments were optimized for <sup>2,3</sup><italic toggle="yes">J</italic><sub>C-H</sub> = 6 Hz. The spectra were recorded in chloroform-<italic toggle="yes">d,</italic> and chemical shifts of the solvent signals at <italic toggle="yes">&#x003b4;</italic><sub>H</sub> 7.27 ppm and <italic toggle="yes">&#x003b4;</italic><sub>C</sub> 77.0 ppm were used as reference signals for spectra calibration. To increase sensitivity, the measurements were conducted in a 5 mm Shigemi tube (Shigemi Inc., Allison Park, PA, USA). The NMR signals are grouped in the tables in the supplemental material and correspond to the numbering in the schemes corresponding to every table.</p></sec><sec id="s3-23"><title><italic toggle="yes">In vitro</italic> antiparasitic activity assays</title><p><italic toggle="yes">In vitro</italic> activity assays against a panel of protozoal parasites, namely <italic toggle="yes">Trypanosoma brucei rhodesiense</italic> (STIB 900), <italic toggle="yes">Trypanosoma cruzi</italic> (Tulahuen C4), <italic toggle="yes">Leishmania donovani</italic> (MHOM/ET/67/L82), and <italic toggle="yes">Plasmodium falciparum</italic> (NF54), and cytotoxicity tests against mammalian cells (L6-cell line from rat-skeletal myoblasts) were performed according to previously described methods (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). All assays were performed in at least three independent replicates.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="d99e450"><caption><title>Reviewer comments</title></caption><media xlink:href="reviewer-comments.pdf"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors thank Joy Birkelbach for the verification and proofreading of the structure elucidation and scientific discussions, Nestor Zaburannyi for genome assembly, and Clemens Schumm for his assistance in the verification of the gene inactivation. Furthermore, we wish to thank Monica Cal, Romina Rocchetti, and Sonja Keller-M&#x000e4;rki for their assistance with the parasite and cytotoxicity assays.</p><p>Research in R.M.&#x02019;s laboratory is funded by the Helmholtz Association (HGF), the German Research Foundation (DFG), the Federal Ministry of Education and Research, Germany (BMBF), and the German Center for Infection Research (DZIF).</p></ack><sec sec-type="data-availability" id="s4-1"><title>DATA AVAILABILITY</title><p>The identified angiolam biosynthetic gene cluster was deposited with GenBank under accession number <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/PP073370" ext-link-type="uri">PP073370</ext-link>.</p></sec><sec sec-type="supplementary-material" id="s4-2"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/spectrum.03689-23" ext-link-type="uri">https://doi.org/10.1128/spectrum.03689-23</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data"><object-id pub-id-type="doi">10.1128/spectrum.03689-23.SuF1</object-id><label>Supplemental material</label><caption><title>spectrum.03689-23-s0001.pdf</title><p>Supplemental methods and results.</p></caption><media xlink:href="spectrum.03689-23-s0001.pdf"/></supplementary-material><supplementary-material id="SuF2" position="float" content-type="local-data"><object-id pub-id-type="doi">10.1128/spectrum.03689-23.SuF2</object-id><label>OPEN PEER REVIEW</label><caption><title>reviewer-comments.pdf</title><p>An accounting of the reviewer comments and feedback.</p></caption><media xlink:href="reviewer-comments.pdf"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>World Health Orgaization (WHO)</collab></person-group>. <year>2023</year>. <article-title>Neglected tropical diseases -- GLOBAL</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://www.who.int/health-topics/neglected-tropical-diseases" ext-link-type="uri">https://www.who.int/health-topics/neglected-tropical-diseases</ext-link></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Mahmoud</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Danton</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Kaiser</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Moreno</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Abd Algaffar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Khalid</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Oh</surname>
<given-names>WK</given-names></string-name>, <string-name><surname>Hamburger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>M&#x000e4;ser</surname>
<given-names>P</given-names></string-name></person-group>. <year>2020</year>. <article-title>Lignans, amides, and saponins from Haplophyllum tuberculatum and their antiprotozoal activity</article-title>. <source>Molecules</source>
<volume>25</volume>:<elocation-id>2825</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/molecules25122825</pub-id><pub-id pub-id-type="pmid">32575379</pub-id>
</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Mahmoud</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>M&#x000e4;ser</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kaiser</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hamburger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Khalid</surname>
<given-names>S</given-names></string-name></person-group>. <year>2020</year>. <article-title>Mining sudanese medicinal plants for antiprotozoal agents</article-title>. <source>Front Pharmacol</source>
<volume>11</volume>:<elocation-id>865</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2020.00865</pub-id><pub-id pub-id-type="pmid">32581814</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Stuart</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Brun</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Croft</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fairlamb</surname>
<given-names>A</given-names></string-name>, <string-name><surname>G&#x000fc;rtler</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>McKerrow</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Reed</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tarleton</surname>
<given-names>R</given-names></string-name></person-group>. <year>2008</year>. <article-title>Kinetoplastids: related protozoan pathogens, different diseases</article-title>. <source>J Clin Invest</source>
<volume>118</volume>:<fpage>1301</fpage>&#x02013;<lpage>1310</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI33945</pub-id><pub-id pub-id-type="pmid">18382742</pub-id>
</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>World Health Organization (WHO)</collab></person-group>. <year>2022</year>. <article-title>World Malaria Report 2022</article-title>. <publisher-name>World Health Organization</publisher-name></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>De Rycker</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wyllie</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Horn</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Read</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Gilbert</surname>
<given-names>IH</given-names></string-name></person-group>. <year>2023</year>. <article-title>Anti-trypanosomatid drug discovery: progress and challenges</article-title>. <source>Nat Rev Microbiol</source>
<volume>21</volume>:<fpage>35</fpage>&#x02013;<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-022-00777-y</pub-id><pub-id pub-id-type="pmid">35995950</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Rao</surname>
<given-names>SPS</given-names></string-name>, <string-name><surname>Barrett</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Dranoff</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Faraday</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Gimpelewicz</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Hailu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Lazdins-Helds</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>M&#x000e4;ser</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mengel</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mottram</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Mowbray</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Sacks</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sp&#x000e4;th</surname>
<given-names>GF</given-names></string-name>, <string-name><surname>Tarleton</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Spector</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Diagana</surname>
<given-names>TT</given-names></string-name></person-group>. <year>2019</year>. <article-title>Drug discovery for kinetoplastid diseases: future directions</article-title>. <source>ACS Infect Dis</source>
<volume>5</volume>:<fpage>152</fpage>&#x02013;<lpage>157</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00298</pub-id><pub-id pub-id-type="pmid">30543391</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wicht</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>Mok</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fidock</surname>
<given-names>DA</given-names></string-name></person-group>. <year>2020</year>. <article-title>Molecular mechanisms of drug resistance in Plasmodium falciparum malaria</article-title>. <source>Annu Rev Microbiol</source>
<volume>74</volume>:<fpage>431</fpage>&#x02013;<lpage>454</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115546</pub-id><pub-id pub-id-type="pmid">32905757</pub-id>
</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Newman</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Cragg</surname>
<given-names>GM</given-names></string-name></person-group>. <year>2020</year>. <article-title>Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019</article-title>. <source>J Nat Prod</source>
<volume>83</volume>:<fpage>770</fpage>&#x02013;<lpage>803</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b01285</pub-id><pub-id pub-id-type="pmid">32162523</pub-id>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Ishiyama</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Otoguro</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Iwatsuki</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Namatame</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nishihara</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Nonaka</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Kinoshita</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Takahashi</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Masuma</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Shiomi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Yamada</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Omura</surname>
<given-names>S</given-names></string-name></person-group>. <year>2009</year>. <article-title>In vitro and in vivo antitrypanosomal activities of three peptide antibiotics: leucinostatin A and B, alamethicin I and tsushimycin</article-title>. <source>J Antibiot (Tokyo)</source>
<volume>62</volume>:<fpage>303</fpage>&#x02013;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ja.2009.32</pub-id><pub-id pub-id-type="pmid">19407848</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Keller</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Plaza</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dubiella</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Groll</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kaiser</surname>
<given-names>M</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2015</year>. <article-title>Macyranones: structure, biosynthesis, and binding mode of an unprecedented epoxyketone that targets the 20S proteasome</article-title>. <source>J Am Chem Soc</source>
<volume>137</volume>:<fpage>8121</fpage>&#x02013;<lpage>8130</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jacs.5b03833</pub-id><pub-id pub-id-type="pmid">26050527</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Held</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gebru</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kalesse</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jansen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gerth</surname>
<given-names>K</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mordm&#x000fc;ller</surname>
<given-names>B</given-names></string-name></person-group>. <year>2014</year>. <article-title>Antimalarial activity of the myxobacterial macrolide chlorotonil A</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>58</volume>:<fpage>6378</fpage>&#x02013;<lpage>6384</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.03326-14</pub-id><pub-id pub-id-type="pmid">25114138</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>van Santen</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Poynton</surname>
<given-names>EF</given-names></string-name>, <string-name><surname>Iskakova</surname>
<given-names>D</given-names></string-name>, <string-name><surname>McMann</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Alsup</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Clark</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Fergusson</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Fewer</surname>
<given-names>DP</given-names></string-name>, <string-name><surname>Hughes</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>McCadden</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Parra</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Soldatou</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Rudolf</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Janssen</surname>
<given-names>E-L</given-names></string-name>, <string-name><surname>Duncan</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Linington</surname>
<given-names>RG</given-names></string-name></person-group>. <year>2022</year>. <article-title>The natural products atlas 2.0: a database of microbially-derived natural products</article-title>. <source>Nucleic Acids Res</source>
<volume>50</volume>:<fpage>D1317</fpage>&#x02013;<lpage>D1323</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkab941</pub-id><pub-id pub-id-type="pmid">34718710</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Fernandez</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Quimque</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Notarte</surname>
<given-names>KI</given-names></string-name>, <string-name><surname>Manzano</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Pilapil</surname>
<given-names>DY</given-names></string-name>, <string-name><surname>de Leon</surname>
<given-names>VN</given-names></string-name>, <string-name><surname>San Jose</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Villalobos</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Muralidharan</surname>
<given-names>NH</given-names></string-name>, <string-name><surname>Gromiha</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Brogi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Macabeo</surname>
<given-names>APG</given-names></string-name></person-group>. <year>2022</year>. <article-title>Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein</article-title>. <source>J Biomol Struct Dyn</source>
<volume>40</volume>:<fpage>12209</fpage>&#x02013;<lpage>12220</lpage>. doi:<pub-id pub-id-type="doi">10.1080/07391102.2021.1969281</pub-id><pub-id pub-id-type="pmid">34463219</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Koller</surname>
<given-names>TO</given-names></string-name>, <string-name><surname>Scheid</surname>
<given-names>U</given-names></string-name>, <string-name><surname>K&#x000f6;sel</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Herrmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Krug</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Boshoff</surname>
<given-names>HIM</given-names></string-name>, <string-name><surname>Beckert</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Schlemmer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sloan</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2023</year>. <article-title>The myxobacterial antibiotic myxovalargin: biosynthesis, structural revision, total synthesis, and molecular characterization of ribosomal inhibition</article-title>. <source>J Am Chem Soc</source>
<volume>145</volume>:<fpage>851</fpage>&#x02013;<lpage>863</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jacs.2c08816</pub-id><pub-id pub-id-type="pmid">36603206</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Schiefer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Schmitz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sch&#x000e4;berle</surname>
<given-names>TF</given-names></string-name>, <string-name><surname>Specht</surname>
<given-names>S</given-names></string-name>, <string-name><surname>L&#x000e4;mmer</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Johnston</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Vassylyev</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>K&#x000f6;nig</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Hoerauf</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pfarr</surname>
<given-names>K</given-names></string-name></person-group>. <year>2012</year>. <article-title>Corallopyronin A specifically targets and depletes essential obligate Wolbachia endobacteria from filarial nematodes in vivo</article-title>. <source>J Infect Dis</source>
<volume>206</volume>:<fpage>249</fpage>&#x02013;<lpage>257</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jis341</pub-id><pub-id pub-id-type="pmid">22586066</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Pogorevc</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Panter</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Schillinger</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jansen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Wenzel</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2019</year>. <article-title>Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic</article-title>. <source>Metab Eng</source>
<volume>55</volume>:<fpage>201</fpage>&#x02013;<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymben.2019.07.010</pub-id><pub-id pub-id-type="pmid">31340171</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>Z-J</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tu</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Huo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>F</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>X</given-names></string-name></person-group>. <year>2023</year>. <article-title>Engineered biosynthesis of complex disorazol polyketides in a streamlined Burkholderia thailandensis</article-title>. <source>ACS Synth Biol</source>
<volume>12</volume>:<fpage>971</fpage>&#x02013;<lpage>977</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acssynbio.2c00610</pub-id><pub-id pub-id-type="pmid">36988632</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Ringel</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Greenough</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Roemer</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Connor</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gutt</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Blair</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kanter</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Strandtmann</surname>
<given-names>MV</given-names></string-name></person-group>. <year>1977</year>. <article-title>Ambruticin (W7783), a new antifungal antibiotic</article-title>. <source>J Antibiot</source>
<volume>30</volume>:<fpage>371</fpage>&#x02013;<lpage>375</lpage>. doi:<pub-id pub-id-type="doi">10.7164/antibiotics.30.371</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Mohr</surname>
<given-names>KI</given-names></string-name></person-group>. <year>2018</year>. <article-title>Diversity of myxobacteria-we only see the tip of the iceberg</article-title>. <source>Microorganisms</source>
<volume>6</volume>:<elocation-id>84</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/microorganisms6030084</pub-id><pub-id pub-id-type="pmid">30103481</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Herrmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fayad</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2017</year>. <article-title>Natural products from myxobacteria: novel metabolites and bioactivities</article-title>. <source>Nat Prod Rep</source>
<volume>34</volume>:<fpage>135</fpage>&#x02013;<lpage>160</lpage>. doi:<pub-id pub-id-type="doi">10.1039/c6np00106h</pub-id><pub-id pub-id-type="pmid">27907217</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Petters</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gro&#x000df;</surname>
<given-names>V</given-names></string-name>, <string-name><surname>S&#x000f6;llinger</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pichler</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Reinhard</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bengtsson</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Urich</surname>
<given-names>T</given-names></string-name></person-group>. <year>2021</year>. <article-title>The soil microbial food web revisited: predatory myxobacteria as keystone taxa?</article-title>
<source>ISME J</source>
<volume>15</volume>:<fpage>2665</fpage>&#x02013;<lpage>2675</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41396-021-00958-2</pub-id><pub-id pub-id-type="pmid">33746204</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Hoffmann</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Krug</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bozkurt</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Duddela</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jansen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Garcia</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gerth</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Steinmetz</surname>
<given-names>H</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2018</year>. <article-title>Correlating chemical diversity with taxonomic distance for discovery of natural products in myxobacteria</article-title>. <source>Nat Commun</source>
<volume>9</volume>:<elocation-id>803</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-018-03184-1</pub-id><pub-id pub-id-type="pmid">29476047</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kohl</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Witte</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kunze</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wray</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Schomburg</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Reichenbach</surname>
<given-names>H</given-names></string-name>, <string-name><surname>H&#x000f6;fle</surname>
<given-names>G</given-names></string-name></person-group>. <year>1985</year>. <article-title>Angiolam A - ein Neues Antibiotikum aus Angiococcus</article-title>. <source>Liebigs Ann Chem</source>
<volume>1985</volume>:<fpage>2088</fpage>&#x02013;<lpage>2097</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jlac.198519851016</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kunze</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kohl</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Hofle</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Reichenbach</surname>
<given-names>H</given-names></string-name></person-group>. <year>1985</year>. <article-title>Production, isolation, physico-chemical and biological properties of angiolam A, a new antibiotic from Angiococcus disciformis (Myxobacterales)</article-title>. <source>J Antibiot</source>
<volume>38</volume>:<fpage>1649</fpage>&#x02013;<lpage>1654</lpage>. doi:<pub-id pub-id-type="doi">10.7164/antibiotics.38.1649</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Sandmann</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sasse</surname>
<given-names>F</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2004</year>. <article-title>Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity</article-title>. <source>Chem Biol</source>
<volume>11</volume>:<fpage>1071</fpage>&#x02013;<lpage>1079</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chembiol.2004.05.014</pub-id><pub-id pub-id-type="pmid">15324808</pub-id>
</mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Panter</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Krug</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Baumann</surname>
<given-names>S</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2018</year>. <article-title>Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria</article-title>. <source>Chem Sci</source>
<volume>9</volume>:<fpage>4898</fpage>&#x02013;<lpage>4908</lpage>. doi:<pub-id pub-id-type="doi">10.1039/c8sc01325j</pub-id><pub-id pub-id-type="pmid">29910943</pub-id>
</mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Hoffmann</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Krug</surname>
<given-names>D</given-names></string-name>, <string-name><surname>H&#x000fc;ttel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>M&#x000fc;ller</surname>
<given-names>R</given-names></string-name></person-group>. <year>2014</year>. <article-title>Improving natural products identification through targeted LC-MS/MS in an untargeted secondary metabolomics workflow</article-title>. <source>Anal Chem</source>
<volume>86</volume>:<fpage>10780</fpage>&#x02013;<lpage>10788</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ac502805w</pub-id><pub-id pub-id-type="pmid">25280058</pub-id>
</mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carver</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Phelan</surname>
<given-names>VV</given-names></string-name>, <string-name><surname>Sanchez</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Garg</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Peng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Watrous</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kapono</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Luzzatto-Knaan</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2016</year>. <article-title>Sharing and community curation of mass spectrometry data with global natural products social molecular networking</article-title>. <source>Nat Biotechnol</source>
<volume>34</volume>:<fpage>828</fpage>&#x02013;<lpage>837</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt.3597</pub-id><pub-id pub-id-type="pmid">27504778</pub-id>
</mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Nothias</surname>
<given-names>L-F</given-names></string-name>, <string-name><surname>Petras</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Schmid</surname>
<given-names>R</given-names></string-name>, <string-name><surname>D&#x000fc;hrkop</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Rainer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sarvepalli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Protsyuk</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Ernst</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tsugawa</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fleischauer</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2020</year>. <article-title>Feature-based molecular networking in the GNPS analysis environment</article-title>. <source>Nat Methods</source>
<volume>17</volume>:<fpage>905</fpage>&#x02013;<lpage>908</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41592-020-0933-6</pub-id><pub-id pub-id-type="pmid">32839597</pub-id>
</mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Gieseler</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Kalesse</surname>
<given-names>M</given-names></string-name></person-group>. <year>2014</year>. <article-title>Synthesis of angiolam A</article-title>. <source>Org Lett</source>
<volume>16</volume>:<fpage>548</fpage>&#x02013;<lpage>551</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ol403423r</pub-id><pub-id pub-id-type="pmid">24341445</pub-id>
</mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Blin</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Shaw</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kloosterman</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Charlop-Powers</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>van Wezel</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Medema</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Weber</surname>
<given-names>T</given-names></string-name></person-group>. <year>2021</year>. <article-title>antiSMASH 6.0: improving cluster detection and comparison capabilities</article-title>. <source>Nucleic Acids Res</source>
<volume>49</volume>:<fpage>W29</fpage>&#x02013;<lpage>W35</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkab335</pub-id><pub-id pub-id-type="pmid">33978755</pub-id>
</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Keatinge-Clay</surname>
<given-names>AT</given-names></string-name></person-group>. <year>2012</year>. <article-title>The structures of type I polyketide synthases</article-title>. <source>Nat Prod Rep</source>
<volume>29</volume>:<fpage>1050</fpage>&#x02013;<lpage>1073</lpage>. doi:<pub-id pub-id-type="doi">10.1039/c2np20019h</pub-id><pub-id pub-id-type="pmid">22858605</pub-id>
</mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Keatinge-Clay</surname>
<given-names>AT</given-names></string-name></person-group>. <year>2007</year>. <article-title>A tylosin ketoreductase reveals how chirality is determined in polyketides</article-title>. <source>Chem Biol</source>
<volume>14</volume>:<fpage>898</fpage>&#x02013;<lpage>908</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chembiol.2007.07.009</pub-id><pub-id pub-id-type="pmid">17719489</pub-id>
</mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kwan</surname>
<given-names>DH</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Schulz</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Popovic</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Sim-Stark</surname>
<given-names>JCC</given-names></string-name>, <string-name><surname>Haydock</surname>
<given-names>SF</given-names></string-name>, <string-name><surname>Leadlay</surname>
<given-names>PF</given-names></string-name></person-group>. <year>2008</year>. <article-title>Prediction and manipulation of the stereochemistry of enoylreduction in modular polyketide synthases</article-title>. <source>Chem Biol</source>
<volume>15</volume>:<fpage>1231</fpage>&#x02013;<lpage>1240</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chembiol.2008.09.012</pub-id><pub-id pub-id-type="pmid">19022183</pub-id>
</mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Kitsche</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kalesse</surname>
<given-names>M</given-names></string-name></person-group>. <year>2013</year>. <article-title>Configurational assignment of secondary hydroxyl groups and methyl branches in polyketide natural products through bioinformatic analysis of the ketoreductase domain</article-title>. <source>Chembiochem</source>
<volume>14</volume>:<fpage>851</fpage>&#x02013;<lpage>861</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cbic.201300063</pub-id><pub-id pub-id-type="pmid">23576424</pub-id>
</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Blake-Hedges</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Pereira</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Cruz-Morales</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Barajas</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Krishna</surname>
<given-names>RN</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>LJG</given-names></string-name>, <string-name><surname>Nimlos</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Alonso-Martinez</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Baidoo</surname>
<given-names>EEK</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gin</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Katz</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Petzold</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Adams</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Keasling</surname>
<given-names>JD</given-names></string-name></person-group>. <year>2020</year>. <article-title>Structural mechanism of regioselectivity in an unusual bacterial Acyl-CoA dehydrogenase</article-title>. <source>J Am Chem Soc</source>
<volume>142</volume>:<fpage>835</fpage>&#x02013;<lpage>846</lpage>. doi:<pub-id pub-id-type="doi">10.1021/jacs.9b09187</pub-id><pub-id pub-id-type="pmid">31793780</pub-id>
</mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Gu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kulkarni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gehret</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Lloyd</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Gerwick</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Gerwick</surname>
<given-names>WH</given-names></string-name>, <string-name><surname>Wipf</surname>
<given-names>P</given-names></string-name>, <string-name><surname>H&#x000e5;kansson</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Sherman</surname>
<given-names>DH</given-names></string-name></person-group>. <year>2009</year>. <article-title>Polyketide decarboxylative chain termination preceded by o-sulfonation in curacin a biosynthesis</article-title>. <source>J Am Chem Soc</source>
<volume>131</volume>:<fpage>16033</fpage>&#x02013;<lpage>16035</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ja9071578</pub-id><pub-id pub-id-type="pmid">19835378</pub-id>
</mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ju</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rajski</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Osada</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Shen</surname>
<given-names>B</given-names></string-name></person-group>. <year>2009</year>. <article-title>Characterization of the tautomycetin biosynthetic gene cluster from Streptomyces griseochromogenes provides new insight into dialkylmaleic anhydride biosynthesis<sup>#</sup></article-title>. <source>J Nat Prod</source>
<volume>72</volume>:<fpage>450</fpage>&#x02013;<lpage>459</lpage>. doi:<pub-id pub-id-type="doi">10.1021/np8007478</pub-id><pub-id pub-id-type="pmid">19191560</pub-id>
</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Sun</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Tomura</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Suzuki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Miyano</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tsuge</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Suh</surname>
<given-names>J-W</given-names></string-name>, <string-name><surname>Iizuka</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Fudou</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ojika</surname>
<given-names>M</given-names></string-name></person-group>. <year>2016</year>. <article-title>Heterologous production of the marine myxobacterial antibiotic haliangicin and its unnatural analogues generated by engineering of the biochemical pathway</article-title>. <source>Sci Rep</source>
<volume>6</volume>:<elocation-id>22091</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep22091</pub-id><pub-id pub-id-type="pmid">26915413</pub-id>
</mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Oliynyk</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stark</surname>
<given-names>CBW</given-names></string-name>, <string-name><surname>Bhatt</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Hughes-Thomas</surname>
<given-names>ZA</given-names></string-name>, <string-name><surname>Wilkinson</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Oliynyk</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Demydchuk</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Staunton</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Leadlay</surname>
<given-names>PF</given-names></string-name></person-group>. <year>2003</year>. <article-title>Analysis of the biosynthetic gene cluster for the polyether antibiotic monensin in Streptomyces cinnamonensis and evidence for the role of monB and monC genes in oxidative cyclization</article-title>. <source>Mol Microbiol</source>
<volume>49</volume>:<fpage>1179</fpage>&#x02013;<lpage>1190</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03571.x</pub-id><pub-id pub-id-type="pmid">12940979</pub-id>
</mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Moln&#x000e1;r</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Schupp</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ono</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zirkle</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Milnamow</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nowak-Thompson</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Engel</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Toupet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Stratmann</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cyr</surname>
<given-names>DD</given-names></string-name>, <string-name><surname>Gorlach</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mayo</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Goff</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Schmid</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ligon</surname>
<given-names>JM</given-names></string-name></person-group>. <year>2000</year>. <article-title>The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90</article-title>. <source>Chem Biol</source>
<volume>7</volume>:<fpage>97</fpage>&#x02013;<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1074-5521(00)00075-2</pub-id><pub-id pub-id-type="pmid">10662695</pub-id>
</mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>J-D</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ying</surname>
<given-names>L-P</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>C-X</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>W-S</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H-B</given-names></string-name>, <string-name><surname>Bai</surname>
<given-names>H</given-names></string-name></person-group>. <year>2011</year>. <article-title>New epothilone congeners from Sorangium cellulosum strain So0157-2</article-title>. <source>Nat Prod Res</source>
<volume>25</volume>:<fpage>1707</fpage>&#x02013;<lpage>1712</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14786419.2011.553719</pub-id><pub-id pub-id-type="pmid">21899481</pub-id>
</mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Chan</surname>
<given-names>YA</given-names></string-name>, <string-name><surname>Podevels</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Kevany</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Thomas</surname>
<given-names>MG</given-names></string-name></person-group>. <year>2009</year>. <article-title>Biosynthesis of polyketide synthase extender units</article-title>. <source>Nat Prod Rep</source>
<volume>26</volume>:<fpage>90</fpage>&#x02013;<lpage>114</lpage>. doi:<pub-id pub-id-type="doi">10.1039/b801658p</pub-id><pub-id pub-id-type="pmid">19374124</pub-id>
</mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Witschel</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rottmann</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kaiser</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brun</surname>
<given-names>R</given-names></string-name></person-group>. <year>2012</year>. <article-title>Agrochemicals against malaria, sleeping sickness, leishmaniasis and chagas disease</article-title>. <source>PLoS Negl Trop Dis</source>
<volume>6</volume>:<elocation-id>e1805</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pntd.0001805</pub-id><pub-id pub-id-type="pmid">23145187</pub-id>
</mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name><surname>Field</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Horn</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fairlamb</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Ferguson</surname>
<given-names>MAJ</given-names></string-name>, <string-name><surname>Gray</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Read</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>De Rycker</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Torrie</surname>
<given-names>LS</given-names></string-name>, <string-name><surname>Wyatt</surname>
<given-names>PG</given-names></string-name>, <string-name><surname>Wyllie</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gilbert</surname>
<given-names>IH</given-names></string-name></person-group>. <year>2017</year>. <article-title>Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</article-title>. <source>Nat Rev Microbiol</source>
<volume>15</volume>:<fpage>217</fpage>&#x02013;<lpage>231</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro.2016.193</pub-id><pub-id pub-id-type="pmid">28239154</pub-id>
</mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><string-name><surname>Green</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Sambrook</surname>
<given-names>J</given-names></string-name></person-group>. <year>2012</year>. <source>Molecular cloning: a laboratory manual</source>. <edition>4th</edition> ed. <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>, <publisher-loc>Cold Spring Harbor, N.Y</publisher-loc>.</mixed-citation></ref></ref-list></back></article>